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ABSTRACT
Platinum has been used as an inorganic medicinal agent with various applications such as
anti cancer agents. Several new targeted Pt(II) conjugates were synthesized having the NGR and
LHRH targeting motif. The platinum conjugates bearing the NGR motif revealed selective
delivery and destruction of cancer cells that had CD13 receptors compared to untargeted
carboplatin drug. The development of targeted chemotherapeutic has opened a new approach for
efficient delivery of antitumor toxins with minimal exposure to normal cells. Several peptide
sequences are known to have the ability to target tumors, for instance NGR motif which home
specifically in solid tumors and has receptors aminopeptidase N (APN), also referred to as CD13
which binds specifically to NGR peptides. Luteinizing hormone-releasing hormone (LHRH),
another targeting moiety, has been found to be more prevalent in tumor cells than normal cells
and has receptors. LHRH sequence was used in the synthesis of targeted curcumin,
phthalocyanine and platinum conjugate.
Another set of platinum complexes synthesized are monofuctional platinum (II)
complexes. The monofuctional platinum complexes are useful in understanding the chemistry of
cisplatin which is bifunctional and forms various adducts on interaction with DNA which are not
well understood. To monitor and understand the interaction of nucleotide with platinum
complexes, complexes with only one reactive sight were synthesized. The tridentate ligands were
characterized by X-ray crystallography, fluorescence and NMR spectroscopy. Interaction of
platinum complexes and nucleotide (5′-GMP) was monitored by NMR to reveal different rate of
rotation about the Pt–N(7) bond depending on the platinum complex studied. These new
complexes have desirable features for assessing the potential of tridentate platinum complexes
for investigating selective monocoordination of metal complexes to DNA and peptides.

ix

CHAPTER 1. INTRODUCTION
Cancer is a disease where a group of cells divide beyond the normal limits. From
American Cancer Society, cancer statistics in 2008 revealed that cancer is the second highest
cause of death exceeded only by heart diseases. Various organic and inorganic compounds have
been found to have anticancer activity. Platinum (II) complexes are examples of inorganic
compounds that are know to have anti- tumor effects. These compounds are known to have
severe side effects and establishing a way to reduce the side effect, understanding and improve
the drug efficacy of some of these drugs has been partially addressed in this work.
1.1 Platinum Complexes
A number of platinum containing drugs have been extensively studied with cisplatin
having remarkable activity against mutants. Cisplatin (Figure 1.1) is used to treat a various
cancers, such as lung, neck, head, and bladder.1,
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The drug is administered to patient

intravenously in sterile brine solution which helps to reduce hydrolysis and retain the cisplatin
intact due to high concentration of chloride ions. Once the neutral cisplatin enters the cell, it
undergoes hydrolysis and the chloro ligands are displaced by water forming positively charged
species. This is made possible by the low concentration of chloride ions in the cell. Cisplatin has
various possible targets in the cell, with include DNA, RNA, enzymes and mitochondria.3, 4 The
effects of cisplatin on RNA and DNA have been extensively studied and established that the
main target is N7 atom of purines.5-7 Once bound to the purines, it affects the replication and
transcription of DNA leading to eventual cell death.
Carboplatin, an analogue of cisplatin, has been approved by the FDA mainly for the
treatment of cancer. It has been reported that both cisplatin and carboplatin (Figure 1.1) have
similar effects against lung and ovarian tumors with the formation of identical adducts with
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DNA. However, lower toxicity was noted for carboplatin and was attributed to the presence of
bidentate ligands which slow down the hydrolysis of carboplatin into potential damaging
species.8 In addition to lower toxicity, carboplatin have been shown to work against cisplatin
resistant malignant.

Figure 1.1. Platinum complexes used in this work.
Dichloro(ethylenediamine)platinum(II) (Pten) is a known derivative of platinum that has
the amine group tethered by an ethylene group. The Pten complex has been shown to be
biologically active against cancer cells.9, 10 Clinical studies on a closely related analogue, such as
ethylenediamino malonate platinum II revealed nephrotoxicity coupled with low potency lead to
the discontinuation of it clinical studies.1, 11, 12
1.2 Curcumin
Curcumin is a polyphenol; found naturally in the perennial herb Curcuma Longa also
known as Turmeric. The curcuminoids which are yellow in color have three major components,
which

include

cyclocurcumin

(77%),

demethoxycurcumin(17%)

and

bisdemethoxycurcumin(3%).11, 13 The curcuminoid complex is also known as yellow ginger and
is mainly grown in Asia. Curcumin can exist in enol form or di-keto form, with enol form being
prevalent in solution stemming an important feature on radiacal-scavanging ability of curcumin.
Curcumin has traditionally been used in food additives/ food flavoring example, Provide curry
spices with distinctive yellow color and flavor, used in coloring of cheese and butter. It has also
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been used as a therapeutic for conditions like respiratory condition, diabetic wounds cough,
running nose, abdominal pain among others with modern scientific research confirming its
effects as an anti-inflammatory, antitumor, antimicrobial, antioxidant and antiarthritic. No studies
have shown any toxicity associated with curcumin irrespective of the concentration.14

Figure 1.2 Structure of various forms of curcumin.
1.3 Polyamine Analogues
The polyamines are organic compounds having two or more primary amine groups. Examples
include ethylenediamine and diethylenetriamine. Chelation of a polyamine to platinum has been
shown to form small molecules that have anti-tumor activity.15, 16 Polyamines play a key role in
growth factor for normal and tumor cells. If cellular polyamine synthesis is inhibited, cell growth
is stopped or severely retarded. In tumor cells the concentration of polyamines is elevated
significantly than the surrounding normal tissues. Polyamines analogues have been proposed as
alternative ways which polyamine metabolism in tumor cells can be blocked.17,

18

Structure-

activity studies of polyamine analogues reveal that slight structure alteration causes remarkable
changes in their biological activity. N-alkylated polyamines have been found to alter the
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neoplastic activity in various human tumor lines. Once the polyamine analogues have been
administered it is thought to deplete polyamines by various mechanisms which include, compete
for uptake, inducing catabolic enzymes and inhibit biosynthesis.19, 20
1.4 Targeted Chemotherapeutic Agents
There are various methods of targeting chemotherapeutics which include small
molecules, hormones, antibody and peptides.21-23 One common modern approach that is being
used to increase the efficacy of chemotherapeutics is peptide targeting. The main aim of this area
is to develop drug vectors capable of targeting tumor cells by specific recognition mechanism for
selective destruction of malignant tissues. Tumor cell contain peptide receptors that are expressed
in higher concentration than normal cell, example; intergrin αvβ3, αvβ5 and aminopeptidase N
(APN/CD13) markers have been demonstrated to home in solid tumors with the aid of phage
display libraries.24 Two peptide sequences Asn-Gly-Arg (NGR) and Arg-Gly-Asp (RGD) were
identified as potential cytotoxic warheads that could deliver selectively to tumor cells.
Another example of targeting sequence is LHRH peptide which has receptor expressed primarily
on the cancerous cells. LHRH is a hormonal decapeptide produced by the hypothalamus, which
plays a pivotal role in the regulation of the reproduction and pituitary gland. Receptors for LHRH
were found primarily on human breast cancer, human ovarian and human prostate cancer. With
the receptors not being expressed in normal cells, this also serves as a great warhead that can be
used to deliver antineoplastic agent to the specific tumor target. A conjugate of LHRH- DOX was
found to be more potent than DOX with reduced toxicity on normal cells.25, 26
The specificity of this cisplatin can be enhanced by efficient delivery of the drug and it’s
analogues to the nucleus of the cancer cells. In this study we present novel targeted peptide
conjugates of platinum(II) and curcumin conjugates to investigate their toxicity effect on tumor
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cells. Recent results on synthesis, characterization, purification, toxicity, selective localization
and cell uptake studies of targeted peptide conjugates will be discussed in following chapters.
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CHAPTER 2. PEPTIDE TARGETING OF PLATINUM ANTI-CANCER DRUGS
2.1 Introduction
Platinum compounds are widely used in cancer chemotherapy.1, 2 Cisplatin, like many
anti-tumor drugs is an FDA-approved drug that is widely used for treatment of many types of
cancers including lung, ovarian, head and neck cancer.3, 4 Carboplatin, an analogue of cisplatin is
used more because it has decreased non-specific toxicity and is active against cisplatin-resistant
tumors.2, 5-9 Both carboplatin and cisplatin have been shown to form similar adducts with DNA
by the formation of covalent bonds with N7 purines. This results in interference with normal
transcription and DNA replication mechanisms, leading to eventual cell death. While these drugs
are effective, they have very serious side effects that include nephrotoxicity, myelotoxicity,
neurotoxicity, vomiting and nausea.10 Certain cancers can also develop resistance to drugs like
cisplatin via efflux pumps as reported by Katano et al.11, 12
One method to make toxic drugs more effective is by altering their target-specific
delivery. A number of peptide sequences are capable of mediating the delivery of therapeutic or
imaging drugs.13, 14 Recently, a doxorubicin (DOX)-peptide conjugate was shown to deliver
DOX to cancerous cells more effectively than free DOX. Specifically, this has been reported for
Asn-Gly-Arg (NGR) and Arg-Gly-Asp (RGD) peptides, which showed improved therapeutic
effectiveness in a breast carcinoma mouse model.15, 16 These DOX-peptide conjugates (DOXRGD and DOX-NGR) also showed reduced toxicity to the liver and heart and caused specific
vascular damage near the tumors. Therefore, DOX-peptide conjugate-treated animals had
increased life expectancies relative to animals treated with DOX alone.17 Similar studies using a
conjugate of 5-fluoro-2'-deoxyuridine (5-FdUrd) and the NGR motif on the breast cancer cell
line MDA-MB-231 and human fibrosarcoma HT-1080 revealed the selective accumulation of
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conjugate in tumor cells that had CD 13 receptors. The 5-FdUrd-NGR motif also exhibited lower
toxicity to normal cells compared to free 5-FdUrd.18 In another study, luteinizing hormone
releasing hormone (LHRH) has been used to target specific receptors that are found mainly in
certain tumor cells.19, 20 Studies on a conjugate of LHRH-DOX and LHRH-2-pyrrolino-DOX
showed increased efficacy, as the drug maintained its highly targeted binding affinity while the
analogues retained their cytotoxic effects on the tumor cells.21-23
Using phage display libraries, it has been discovered that several peptide sequences have
the ability to target tumors.24 For example, RGD-containing peptides have been shown to bind to
integrins and also to reside preferentially in some tumor cell types.25 In another study, the NGR
motif was identified as a peptide that uniquely homed specifically to solid tumors in murine
breast carcinoma models and that bound strictly to the endothelium of angiogenic blood vessels.26
The NGR motif may be superior to the RGD-related motif for targeting, due to the type of cells
that express the αVβ3 and αVβ5 integrins, which may lead to nonspecific toxicity.25 Haubner et al.
revealed that radiolabeled RGD peptide was found to concentrate rapidly in the liver, which can
lead to liver toxicity in drugs that are based on RGD targeting, hence limiting the usefulness of
these drugs.25
Angiogenesis occurs at extremely low levels in the adult organism; however, malignant
tumors are an exception, with endothelial cells proliferating beyond the normal limits. In such
tumors, new blood vessels are assembled, and this is required for tumor growth.26, 27 Modulating
the growth of blood vessels is one of the effective ways to control the growth and spread of
tumors. Therefore, the search for targets that can regulate angiogenesis is important.
Aminopeptidase N (APN), also referred to as CD13, is a cell-surface antigen that binds
specifically to NGR peptides.28, 29 CD13/APN is expressed exclusively on the endothelial cells of
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angiogenic tissues and the vasculature of various carcinomas including kidney, colon, pancreas,
prostate and lung30-33. It is not expressed in normal vasculature, which explains the tumor-specific
destination of the NGR peptide.3, 34
Targeting the delivery to defined cancer cells can enhance the specificity of cisplatin and
its analogues. By conjugating the water-soluble, cyclic peptide CNGRC to the conventional
drugs cisplatin and Dichloro(ethylenediamine)platinum(II) (PtenCl2), we propose to generate
greater selectivity, increased specificity to cancer cells, and reduced toxicity to normal tissues. In
this work, we describe the preparation of several malonyl CNGRC peptides and their platinum
complexes and evaluate their specific targeting on tumor cells with CD13 receptors. Our final
target compound is shown in Figure 2.1:

Figure 2.1. CNGRC-conjugate ligands that have been synthesized and examined in this chapter
2.2 Experimental Section
2.2.1 Starting Materials. All starting materials listed below were obtained from commercial
sources and used without further purification: Di-tert-butyl malonate, dry solvents, AgNO3, 3bromopropylphthalimide,

dichloro(ethylenediamine)platinum(II),
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cis-Diammineplatinum(II)

dichloride and glutaric anhydride were obtained from Aldrich (Milwaukee WI), Fmoc-11-amino3,6,9-trioxaundecanoic acid (miniPEG) was obtained from Peptide International (Louisville,
KY), and all amino acids and coupling reagents were obtained from Novabiochem (Gibbstown,
NJ).
2.2.2 NMR Spectroscopy. 1H NMR spectra were recorded on either 300 or 400 MHz
spectrometers. Peak positions are referenced to TMS. All NMR data were processed with
XWINNMR and Mestre-C software.
2.2.3 HPLC. HPLC was performed using a Water 600E multisolvent delivery system with a
model 486 tunable detector controlled by Empower software and Water Deltaprep system, with
detection at 220 nm. Different columns were used for analysis and purification of the peptides.
Analytical and semi-preparative chromatography was performed on a Delta-Pak C4 (5 µm;100
Aº) reverse phase column (8× 100 mm) at 1 mL/min (column 1). Preparative HPLC was
performed on Waters Delta-Pak C4 (15 µm;100 Aº) reverse phase column (25 × 100 mm) at 15
mL/min (column 2). Linear gradients of 0.1% aqueous TFA in H2O (Eluent A) and 0.1% TFA in
MeCN (Eluent B) in all HPLC were used.
2.2.4 Mass Spectrometry. Compounds were analyzed using MALDI-TOF on a Bruker Proflex
III instrument with Xmass software, or using ESI on an Agilent Technologies instrument,
processed with Analyst QS1.1.
2.2.5 Inductive Coupled Plasma-Optical Emission Spectroscopy. Platinum uptake was
analyzed using a Varian, Vista MPX CCD simultaneous spectrometer. PlasmaCal Pt (1000
µg/ml) from SCP Science was used for calibration by diluting it to standard solutions of known
concentration.
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2.2.6 Synthesis
2.2.6.1 Peptide Synthesis. All peptides were synthesized using standard Fmoc solid phase
chemistry. PAL-PEG-PS (Peptide Amide Linker resin: 0.2 mmol, 0.24 mmol/g loading) was
placed in a normal resin column and washed with DMF in continuous flow mode using a Pioneer
Peptide Synthesizer. The sidechain-protected aminoacid derivatives used in the sequence were
resin, Fmoc-Cys(Acm)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, and FmocCys(Acm)-OH (Figure 2.2). Fmoc-mini-peg-3TM solubilizing agent and the derivatized malonate
linker di-tert-butyl 2-(3-glutaricaminopropyl)malonate were used, depending on the peptide
sequence. All coupling utilized four equivalents each of amino acids, malonate, and PyAOP,35
dissolved in 0.5 M DIEA in DMF (0.25 M final concentration) for 1 hour at room temperature.
DMF was used for washing between reaction times, and a minimal preactivation time was used
in the coupling. The Fmoc group was removed using 20% piperidine in DMF for 5 min. A
further washing step yielded the desired peptide.
2.2.6.2 Synthesis of CNGRC-Mal (1). In an attempt to synthesize CNGRC-Mal, we synthesized
cyclic CNGRC using the method described by Anizon et al. using NovaSyn TGT alcohol resin
(0.20 mmol, 0.20 mmol/g loading).17 Conjugation of CNGRC with di-tert-butyl 2-(3aminopropyl)malonate was unsuccessful (Scheme 2.1).
2.2.6.3 Synthesis of Mal-Glut-CNGRC (2). Using standard Fmoc chemistry, we synthesized
Mal-Glut-CNGRC using the procedure described in the peptide synthesis section, using PALPEG-PS resin without the Fmoc-mini-peg-3TM solubilizing group. Coupling the peptide with ditert-butyl 2-(3-glutaricaminopropyl)malonate gave crude Mal-Glut-CNGRC peptide, which was
purified by reverse phase HPLC on column 1, using a linear gradient from 5% to 70% B eluent in
60 min, tR 11 min. The product gave the expected (M+H)+ Peak at 807.2893, as calculated for
C29H48N11O12S2.807.2925 (see Appendix B). Using the procedure described for the preparation of
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cyclic mPeg-CNGRC-Pt, the peptide was reacted with cis-[Pt(NH3)2(H2O)2]2+(NO3)2 to give an
insoluble yellow solid (Scheme 2.2). This was not suitable for further characterization.

Figure 2.2 Structures of the amino acids used in the synthesis.
2.2.6.4 Synthesis of Di-tert-butyl 2-(3-Phthalimidopropyl)malonate (3). Di-tert-butyl 2-(3phthalimidopropyl)malonate was synthesized by a known method (Scheme 2.3) with slight
modifications.36 NaH (0.38 g, 16 mmol) was suspended in dry THF (100 mL), and dry di-tertbutyl malonate (4.4 mL, 20 mmol) was added to the reaction mixture (with stirring) until gas
evolution ceased. A solution of 2.68 g of 3-bromopropylphthalimide (10 mmol) was added
dropwise to the reaction mixture, followed by stirring overnight. The THF was removed by
evaporation, and the product was redissolved in CH2Cl2 and washed with 5% aqueous acetic
acid. The organic fractions were combined, dried over MgSO4 and concentrated. The final
product was isolated using silica column chromatography (95% Hexane, 5% ethyl acetate). Di-
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tert-butyl 2-(3-phthalimidopropyl)malonate was crystallized using a mixture of CH2Cl2 and
hexane to give colorless plates (see Appendix B). The yield was 80% (3.22 g). Spectroscopic
data obtained for this compound were in agreement with literature values.36
2.2.6.5 Synthesis of Di-tert-butyl 2-(3-aminopropyl)malonate (4). Compound 4 was prepared
as described by Aronov et al.36 Di-tert-butyl 2-(3-phthalimidopropyl)malonate was deprotected
using hydrazine to give di-tert-butyl 2-(3-aminopropyl)malonate. The 1H NMR spectrum of
compound 4 (Scheme 2.3) in CDCl3 matched the reported values.
2.2.6.6 Synthesis of Di-tert-butyl 2-(3-glutaricaminopropyl)malonate (5) Compound 5 was
synthesized as previously described in the literature36. Glutaric anhydride was used for alkylation
in this reaction, yielding di-tert-butyl 2-(3-glutaricaminopropyl)malonate (see Appendix B). The
yield was 92%.1H NMR (CDCl3) (ppm): 3.27 (q, 2H), 3.14 (t, 1H), 2.41 (t, 2H), 2.28 (t, 2H),
1.98 (m, 2H), 1.81(m, 2H), 1.56 (m, 2H), 1.45(s, 18H).
2.2.6.7 Synthesis of Cyclic mPeg-CNGRC-mal (6). After synthesizing the linear mPegCNGRC-mal peptide and confirming its purity, the resin was suspended in DMF (60 mL), and
the reaction mixture cooled to 0 oC in an ice bath before the addition of I2 (10 equiv). The
mixture was stirred at 0 oC for 2 h, filtered and washed with DMF (10 × 10 mL) and CH2Cl2 (10
× 10 mL). Using a cocktail of TFA:phenol:water:TIPS (88:5:5:2) (15 mL), the peptide was
cleaved from the resin, precipitated and dried under vacuum to give crude peptide 6. The crude
peptide was purified using reverse phase HPLC on column 1 with a linear gradient from 5% to
70% B eluent in 60 min, tR 28 min. This yielded cyclic mPeg-CNGRC-mal (6) at 35% yield.
TOF-MS (ESI) gave a signal at 1184.4764 (M + H+) calculated for C45H77N13O20S2 is 1184.4849
(see Appendix B).
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2.2.6.8 Synthesis of Cyclic mPeg-CNGRC-Pt (7). Cyclic mPeg-CNGRC-mal was dissolved in
water, and the pH of the solution was adjusted to 7, by titration with 1M NaOH (Scheme 2.4). A
solution of cis-[Pt(NH3)2(H2O)2]2+(NO3)2 was made by stirring cis-PtCl2(NH3)2 and AgNO3
vigorously overnight in water in the dark. A precipitate was formed (AgCl) and then filtered to
yield cis-[Pt(NH3)2(H2O)2]2+(NO3)2

37,38

A 2-fold excess of cis-[Pt(NH3)2(H2O)2]2+(NO3)2 was

reacted with compound 6 to form the crude cyclic mPeg-CNGRC-Pt conjugate (7), which was
then purified by gel filtration on Sephadex-G10 column to yield the final product at 15% yield.
TOF-MS (ESI) gave a signal at 1412.4913 (M + H+) calculated for C45H81N15O20PtS2 is
1412.4955 (see Appendix B).
2.2.6.9 Synthesis of Cyclic mPeg-CNGRC-Pten (8). Cyclic mPeg-CNGRC-mal was dissolved
in water, and the pH of the solution was adjusted to 7, by titration with 1M NaOH. Cis[Pt(en)(H2O)2]2+(NO3)2 was synthesized by stirring Pt(en)Cl2 and AgNO3 vigorously overnight,
in water in the dark. A precipitate was formed (AgCl) and then filtered to yield cis[Pt(en)(H2O)2]2+(NO3)2.39-41 A 2-fold excess of cis-[Pt(en)(H2O)2]2+(NO3)2 was reacted with
compound 6 to yield crude cyclic mPeg-CNGRC-Pten conjugate, which was then purified by gel
filtration on Sephadex-G10 column to yield cyclic mPeg-CNGRC-Pten (8) at 10-12% yield.
TOF-MS (ESI) gave a signal at 719.7571 (M + H)2+ calculated for C47H83N15O20PtS2 is 719.7571
(see Appendix B).
2.2.6.10 Synthesis of Cyclic mPeg-CNGRC (9). The peptide was assembled as described in the
peptide

synthesis

section,

without

the

malonate

linker

di-tert-butyl

2-(3-

glutaricaminopropyl)malonate. The crude peptide was purified by reverse phase HPLC on
column 1, with a linear gradient from 5% to 70% B eluent in 60 min, tR 12 min, yielding cyclic
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mPeg-CNGRC (9) at a 38% yield. ESI-MS (TOF) gave a signal at 927.4032 (M + H+) calculated
for C34H62N12O14S2 is 927.4023 (see Appendix B).
2.2.7 Cell Culture Studies
2.2.7.1 Cell Culture. The prostate cancer cells LNCap (CRL-1740) and PC-3 (CRL-1435) were
obtained from the American Type Culture Collection (Manassas, VA). Penicillin, streptomycin,
RPMI 1640, and fetal bovine serum (FBS) were obtained from Invitrogen (Grand Island, NY).
Both cell lines were cultured in RPMI 1640 supplemented with 10% FBS, 100 units/mL
penicillin and 100 µg/mL streptomycin.
2.2.7.2 Fluorescence Microscopy. PC-3 and LNcap cells were seeded on 6-well plates (500,000
cells/well) and incubated for 24 h in RPMI 1640 media. The cells were treated with 200 µM of
carboplatin, a mixture of carboplatin and free peptide, and Pt-peptide conjugates 7 and 8 for 48
h. After incubation, the cells were washed once with RPMI and then stained with JC-1 dye for 30
min. The stained cells were analyzed using a Leica DM RXA fluorescent microscope with
Xenon lamp illumination, using a 40 x dip objective with an N.A. of 0.80. The filter cube for the
green channel had the following characteristics: a 480/40 excitation filter, a 527/30 emission
filter and a 505nm dichroic mirror. The filter cube used for the red channel had the following
characteristics: a 537/45 excitation filter, an LP 590 emission filter, and a 580 nm dichroic
mirror.
2.2.7.3 Cytotoxicity Assay. The cytotoxicity of the free carboplatin and two platinum conjugates
(cyclic mPeg-CNGRC-Pt (7) and cyclic mPeg-CNGRC-Pten (8)) was assayed using the MTT (3(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay as described.42 Briefly,
2,000 cells/well were incubated in 96-well plates in triplicate, using different concentrations of
platinum complexes in a cell growth medium. Three wells were used as controls, receiving an
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equivalent volume of medium alone. In the first experiment, the cells were treated with different
concentrations (0 μM, 50 μM, 150 μM, 200 μM and 300 μM) of carboplatin, peptide 6, and Ptpeptide conjugates 7 and 8 for 4 h. After this period, the regular cell growth medium was
replaced, and the cells were incubated for a further 48 h. In another set of experiments, the cells
were treated with the same set of compounds at different concentrations for 48 h. After 48 h, in
both sets, a solution of MTT (5 mg/ml in PBS) was added to each well, and the cells were
incubated for 2 h at 37οC. The cells were then lysed using a lysis buffer (20% SDS and 50%
DMSO). The lysed cells were incubated for 3 h at 37οC, before the absorbance of the cell
suspension was measured at 590 nm using an MRX Revelation 96-well multiscanner (Dynex
Technologies, Chantilly, VA).
2.2.7.4 Drug Uptake Measurements. One million PC-3 and LNcap cells were plated in a 6-well
plate one day prior to the treatment so that they had time to adhere to the plate. On the next day,
the cells were treated with fresh medium containing 200 μM carboplatin, and Pt-peptide
conjugates 7 and 8 for 24 h. After incubation, the cells were washed with PBS once, and the cells
were collected in a tube for further analysis. Samples were dissolved in 0.25 ml nitric acid (trace
metal grade) and heated for 2 h at 60 οC for digestion. Upon cooling, approximately 5 mL of
deionized water was added to dilute the samples to the minimum volume required for the ICP
spectrometer.
2.2.7.5 Cell Competition Assay
Using various concentrations of mPeg-CNGRC (9), a cell competition assay for carboplatin and
conjugates 7 was carried out using the MTT assay. A quantity of 2,000 cells/well was incubated
in a 96-well plate in triplicate using various concentrations of the free peptide mPeg-CNGRC (9)
(1 mM, 2 mM, 4 mM,, 8 mM and 10 mM) for 45 minutes. This was followed by the addition of
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200 μM of carboplatin or conjugate 7 for 48 h. The plate was analyzed as described in the cell
cytotoxicity assay.
2.3 Results and Discussion
Using PAL-PEG-PS resin, a pegylated CNGRC was synthesized in order to evaluate the
effectiveness of the drug delivery of the platinum analogues. We chose this system (pegylated
peptide) to increase the solubility and to provide additional spacing of the platinum ligand from
the targeting peptide ligand. Figure 2.3 shows the two designs that we tested for the formation of
Pt-peptide complexes, with design B being the more successful of the two.

Figure 2.3. CNGRC model conjugate with platinum pro-drug
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Our initial attempt was to couple the cyclic CNGRC peptide with di-tert-butyl 2-(3aminopropyl)malonate using solution phase chemistry by conjugating the free carboxylic end of
the cysteine with the free amine end of di-tert-butyl 2-(3-aminopropyl)malonate (Scheme 2.1).
The Cyclic CNGRC peptide was prepared as described by Anizon et al.17 where the trityl alcohol
resin was converted to the trityl chloride derivative with acetyl chloride. This was followed by
loading of the Fmoc-Cys(Acm)-OH onto resin, resulting in a 0.14 mmol/g (70%) loading yield.
The resin was treated with Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, and FmocCys(Acm)-OH to give crude CNGRC in high yield. The HPLC chromatogram and the mass
spectrum revealed the expected (M+H)+ peak at 550.76, which was in agreement with the
reported values. Di-tert-butyl 2-(3-aminopropyl)malonate was prepared as described in the
experimental section using a slight modification of the Aronov method.36 The malonate was
alkylated using a strong base to give product in 80% yield. A similar synthesis was achieved by
the Aronov group using KOt-Bu as a base; however, using a stronger base (NaH) in the reaction
improved the yields from 60% to 80%. A twofold excess of di-tert-butyl malonate was used to
ensure monoalkylation and the ease of separation between the malonate and di-tert-butyl 2-(3phthalimidopropyl)malonate. The excess of di-tert-butyl malonate that was used was easily
removed by column chromatography.36 Attempts to couple the cyclic peptide CNGRC and ditert-butyl 2-(3-aminopropyl)malonate using various coupling reagents were unsuccessful
(Scheme 2.1). We do not understand why the reaction failed, as similar reactions between
CNGRC and DOX with similar functional groups have been successful.17 Analysis of the crude
product revealed high amounts of the starting materials, including CNGRC, di-tert-butyl 2-(3aminopropyl)malonate, and coupling reagents.
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Scheme 2.1. Coupling of CNGRC with di-tert-butyl 2-(3-aminopropyl)malonate.
In order to overcome the above problem, we used PAL-PEG-PS resin. This enabled us to
conjugate the linker on the N terminus of peptide resin, thereby avoiding solution phase
chemistry in the conjugation of the linker to the peptide CNGRC, as shown in Scheme 2.2. To
achieve this synthesis, malonate linker with a carboxylic acid end (5) was synthesized using
glutaric anhydride and di-tert-butyl 2-(3-aminopropyl)malonate (4), as shown in Scheme 2.3.
Using general Fmoc chemistry, the peptide was assembled using the same amino acids described
above. This was then conjugated to di-tert-butyl 2-(3-glutaricaminopropyl)malonate and cyclized
on the solid support to yield (Mal-Glut-CNGRC) as a single product. It eluted in 11 min on
HPLC, demonstrating that it could be easily purified. Mass spectral analysis confirmed the
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identity of the cyclic Mal-Glut-CNGRC, as it had a (M+H)+ peak at 807.2893. Platination of the
purified Mal-Glut-CNGRC using cis-[Pt(NH3)2(H2O)2]2+(NO3)2 gave an insoluble yellow
compound in most solvents, including water, DMSO, DMF, MeOH, acetone, MeCN, CH3Cl, and
CH2Cl2.

Scheme 2.2. Platination reaction using Mal-Glut-CNGRC
Our third and final approach was to pegylate the CNGRC sequence by adding miniPEG
to each end of the sequence to improve the solubility of the compound and to provide additional
spacing of the Pt-ligand from the targeting peptide ligand. Various studies have shown that
pegylation does not affect targeting and may have other positive effects, such as an increase in
stability that reduces the chance of the drug being effluxed and that it reduces or eliminates
immunogenicity.36 The linear peptide was cyclized on a solid support and cleaved to give target
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compound 6 (Scheme 2.4), which was purified by HPLC and confirmed by mass spectra to have
the expected (M+H)+ peak at 1184.4764.

Scheme 2.3. Synthesis of Di-tert-butyl 2-(3-glutaricaminopropyl)malonate
2.3.1 Platinum Complexes
Platination with a twofold excess of activated cis-[Pt(NH3)2(H2O)2]2+(NO3)2 and cis[Pt(en)(H2O)2]2+(NO3)2 using a standard procedure gave Pt-Peptide conjugates 7 and 8, as shown
in Scheme 2.4. The platinum complexes could not be purified by HPLC using either an acid or a
neutral solvent system because the platinum complexes dissociated. The products were therefore
purified by gel filtration to remove the excess platinum. Fractions containing the Pt-peptide
complex in water were identified by ESI-MS and then combined and lyophilized to give pure
platinum complexes for cyclic mPeg-CNGRC-Pt (7) and cyclic mPeg-CNGRC-Pten (8) at a 1015% yield. Mass spectra revealed the expected (M+H)+ peak at 1412.4913 for conjugate 7 and
the (M + 2H)2+ peak at 719.7571 for conjugate 8. The two carboxylic acid groups at the end of
the peptide enabled the formation of platinum chelate, binding in a bidentate fashion. During the
study, we noticed that platinum complex 7 was not very stable in PBS at -20°C and formed
precipitates after a day of storage. Any experiment using complex 7 had to be prepared freshly
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and used immediately. Platinum complex 8 was stable at -20°C, and the stock solutions prepared
could be used in later experiments. Both platinum conjugates were stable as lyophilized samples
at -20°C and fresh samples were made by reconstituting the dry samples to the desired
concentration. The stability of the complexes was confirmed by mass spectrometry. Scheme 2.4
shows the formation of the final platinum complexes synthesized.

Scheme 2.4. Synthesis of cyclic mPeg-CNGRC-Pt (7) and cyclic mPeg-CNGRC-Pten (8), where
Fmoc mini peg-3 is

.
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2.3.2 In vitro Studies on Pt-conjugates: Toxicity and Uptake

Figure 2.4. The effect of carboplatin (free peptide), cyclic mPeg-CNGRC-mal (6), the mixture of
carboplatin and mPeg-CNGRC (9), and the Pt-peptide conjugates; cyclic mPeg-CNGRC-Pt (7)
and cyclic mPeg-CNGRC-Pten (8) on the proliferation of prostate cancer PC-3 (CD13 positive)
cells and LNcap (CD13 negative) cells. (A) PC-3 cells and (B) LNcap cells were exposed to the
compounds listed and incubated for 48 h at different concentrations. (C) A comparison of %
viability of the PC-3 and LNcap cells at 150 µM ligand concentration. The data represents three
independent experiments, P < 0.04 vs. carboplatin and is statistically significant (P < 0.05). The
statistical significance was determined using the t-test.
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It has been shown that the NGR motif binds specifically to the CD13 receptors that are
expressed on some tumor cells. We examined the effect of the free peptide in a control
experiment to determine the toxicity of the peptide. MTT-reduction levels were normalized to the
positive control. As shown in Figure 2.4A, the free peptide (6) was not toxic to the PC-3 cells
and caused a slight increase in the MTT assay, suggesting that the PC-3 receptors were activated
by the NGR ligand. As expected, the targeted Pt-peptide conjugates 7 and 8 were more toxic to
the PC-3 cells at all concentrations tested compared to the untargeted carboplatin (even at
concentrations as low as 50 μM). Pt-conjugate 8 shows the highest effect on the suppression of
cell proliferation, followed by Pt-conjugate 7 and carboplatin. Carboplatin was the least toxic to
PC-3 cells of this series of platinum compounds, indicating that the platinum complexes bearing
the CNGRC sequence are more effective at suppressing tumor cell proliferation. The %
inhibition caused by the mixture of mPeg-CNGRC (9) and carboplatin was similar to that caused
by carboplatin alone, suggesting that there was no effect of the peptide on the effectiveness of
carboplatin. Treatment of LNcap cells with this series of platinum complexes did not have much
effect on the proliferation of the cells, suggesting little platinum uptake due to lack of CD13
receptors (Figure 2.4B). No conclusions could be drawn from the cell toxicity data, as the LNcap
cells were barely sensitive to carboplatin. A very high dose of carbopaltin 200 µM showed 10%
cell killing, therefore, the result cannot be interpreted. Comparison between the two cell lines,
PC-3 and LNcap, (Figure 2.4C), revealed a clear difference between the targeted and untargeted
platinum complexes, when used at 150 µM. Less than 50% of the PC-3 cells were viable when
exposed to the targeted Pt-peptide conjugates, compared to greater than 60% for the untargeted
carboplatin drug. The targeted and untargeted platinum complexes had no significant difference
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in their effect on the % viability of the LNcap cells. The free peptide 6 did not show any
activation of the LNcap cell line in comparison to the PC-3 cell line.
The carboplatin, free peptide 6, Pt-peptide conjugate 7 and Pt-peptide conjugate 8 were
also tested at various concentrations (50 µM, 150 µM, 200 µM and 300 µM) by continuous
exposure for 4 h followed by incubation for 48 h at 37°C in cell growth media (see appendix B)
for both cell lines. Overall, similar trends on % viability were observed, with a lower toxicity that
shows that the uptake of the drug starts after as little as 4 h after incubation with the compounds.

Figure 2.5. Competition assay on PC-3 cancer cells using carboplatin and conjugate 8 with free
peptide 9
Figure 2.5 demonstrates that the free peptide had no cytotoxic effect on the PC-3 cells. A slight
increase in the % viability suggests the activation and nourishment of the PC-3 cells. Carboplatin
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and conjugate 8 were incubated with various concentration of mPeg-CNGRC (9) as described in
the methods. Incubation of carboplatin with various concentration of free peptide 9 had the same
effect on the % viability irrespective of the amount of free peptide (9) used. Incubation of
conjugate 8 with various concentrations of free peptide (9) showed that the free peptide was
competing with conjugate 8 in targeting the CD 13 receptors. With an initial 5-fold excess of free
peptide (9), conjugate 8 was more cytotoxic than free carboplatin, but with a 10-fold excess, the
free peptide (9) was able to compete away the effect of conjugate 8 in comparison to carboplatin.
A further 50-fold increase in the free peptide concentration resulted in the elimination of the
cytotoxic effect from conjugate 8. The results also demonstrate that the CNGRC motif
contributes to the accumulation of platinum in the tumor cells, causing a significant difference in
the suppression of the proliferation of PC-3 tumor cells.

Figure 2.6. A study on the uptake of PC-3 (CD13 positive) and LNcap (CD13 negative) cancer
cells. One million cells were incubated with carboplatin, and Pt-peptide conjugates 7 and 8 for
24 h at 200 μM. The results were analyzed as explained in the method section.
For cell death to occur, it is believed that platinum coordinates with N7 of the purines forming a
1,2-intrastand adduct, causing the destacking and bending of DNA that leads to eventual cell
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death. To confirm the cell toxicity results obtained above, the uptake of platinum by LNcap and
PC-3 cells was determined by exposing the cells to 200 µM carboplatin, Pt-peptide conjugate 7
and Pt-peptide conjugate 8 for 24 h. The greatest uptake occurred with platinum complex 7
followed by complex 8, and the least uptake occurred with carboplatin, in PC-3 cells. Uptake in
LNcap cells followed a similar trend, but at much lower levels compared to PC-3. The uptake of
untargeted carboplatin was determined to evaluate the difference with the targeted complexes.
From the data in Figure 2.6, platinum uptake by the PC-3 cells was 12-fold greater when using
conjugate 7 and 3-fold greater when using conjugate 8, compared to untargeted carboplatin. The
uptake of platinum by the LNcap cells was 5-fold and 2-fold greater when Pt-peptide conjugates
7 and 8 were used, respectively, than when carboplatin was used. Figure 2.6 also reveals that the
carboplatin uptake by PC-3 was double that of the LNcap cells, and similarly, the uptake of Ptpeptide conjugates 7 and 8 was 5 and 4-fold greater when using PC-3 cells as compared to the
LNcap cells, respectively. These results clearly suggest that the PC-3 cells seem to be more
susceptible to platinum uptake due to the presence of the CD13 receptors.
Another notable observation was the effect of targeted platinum complexes at the lowest
concentration tested (50 μM) on PC-3 cells. A concentration of 200 μM showed the most
substantial effect on cell proliferation (Figure 2.4). These results suggest that higher uptake of Pt
leads to greater suppression of the proliferation of PC-3 cells. Our results are in agreement with
other groups, who have shown that the CNGRC motif contributes to the increased intracellular
concentration of drugs that are attached to this motif, due to targeting to CD13 positive cells. A
5-FdUrd conjugate bearing the homing peptide CNGRC was found to penetrate into the CD13
positive cells, HT-1080, but not to the CD13 negative cells, MDA-MB-231. This enhanced the
selective accumulation of 5-FdUrd, resulting in more effective immunotherapy.18
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High uptake seems related to the toxicity of Pt-peptide conjugate 7 and 8, supporting the
hypothesis that high uptake of platinum drugs results in high cytotoxicity. Our major concern
during this experiment was to ensure that the cisplatin/carboplatin moiety detaches from the
carrier at the right place at the right time. With this in mind, we chose carboplatin as our control
drug in the experiment because we expected that our targeted compound would release the drug
in a manner similar to carboplatin. When other targeting ligands have been used, cisplatin uptake
and targeted platinum uptake in some cell lines show comparable values and trends to our results,
where targeted drugs had a higher uptake than untargeted platinum drugs.43-46 To our surprise,
even though the uptake of Pt complex 8 was lower than that of Pt complex 7, complex 8 was
more toxic than complex 7. This suggests that either the activation mechanism or the delivery
pathway of complexes 7 and 8 might be different. Clinical trials of ethylene diamine platinum
complexes were suspended, as previous animal studies have shown high nephrotoxicity relative
to cisplatin.47,
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Our findings similarly show that even with low uptake of complex 8 (an

analogue of the ethylene diamine platinum complexes), substantial toxicity was observed. This
shows that care should be taken when interpreting whether high platinum uptake has a direct
relationship with cell death, and that more studies need to be done on this area.
2.3.3 Fluorescence Microscopy
The cell toxicity was evaluated using fluorescence microscopy (Figure 2.7) and the JC-1
membrane potential kit, which measures the mitochondrial membrane potential. Images A and D
show healthy cells grown in media, allowing the JC-1 dye to aggregate resulting in red
fluorescence. The results shown in Figure B confirmed that targeted Pt-peptides and conjugates 7
(Image B) and 8 (see Appendix B) cause a decrease in the membrane potential, thereby causing
death by apoptosis in the PC-3 cell line.
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Figure 2.7. Fluorescence microscopy of cells that have been treated with various compounds,
incubated for 48 h at 37°C and then imaged by JC-1 staining after a further 30 min of incubation.
Images A and D; PC-3 and LNcap cells, respectively, treated with RPMI media only. Images B
and E; PC-3 and LNcap cells, respectively, treated with 200 µM of Pt-peptide conjugate 8 in
RPMI media. Images C and F; PC-3 and LNcap cells, respectively, treated with 50% DMSO.
Images G and H; PC-3 cells incubated with a mixture of carboplatin/free peptide 9 (1:50) and
carboplatin only, respectively.
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Image E however, reveals that complexes 7 and 8 had either a minimal or no effect on LNcap
cells, which do not have CD13 receptors. This is evident from the intense, red fluorescence in
both untreated LNcap cells (D) and LNcap cells that had been treated with Pt-peptide conjugate
8 (E). As the toxicity is less towards the CD13-negative cell line (LNcap), this study suggests a
lower toxicity for normal cells, which have no receptors. Apoptotic and dying cells have a low
membrane potential resulting in a green fluorescence which is evident in images C and F.
Images G and H show PC-3 cells treated with mixture of carboplatin/free peptide 9 (1:50) and
carboplatin alone, respectively. The images show more viable cells when compared to PC-3 cells
treated with targeted conjugate 8.49
2.4 Conclusion
Our work focused on synthesizing novel targeted Pt-peptide conjugates using the NGR
motif and a malonaly linker. The advantage of the targeted platinum analogues that we
synthesized and studied in this work is that they increase the selectivity and specificity for cancer
cells and are less toxic to normal tissues. This study reveals two new low molecular weight Ptpeptide conjugates that effectively deliver cisplatin and PtenCl2 to tumor cells, thereby reducing
the side effects on normal cells and increasing the toxicity towards tumor cells. Pegylation of the
peptide CNGRC allowed us to study the carrier at physiological conditions; however, the
solubility problem did not allow us to compare the difference in cytotoxicity of the non-pegylated
conjugate relative to one without the miniPEG. The presence of the bidentate dicarboxylate
ligand in carboplatin has been shown to slow the degradation of carboplatin into potentially
damaging derivatives, thereby reducing nonspecific toxicity and increasing the potency relative
to cisplatin.50, 51 With the aid of the miniPEG group and the bidentate ligand, we show that Pt-
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peptide complexes 7 and 8, which are analogues of carboplatin, were able to target tumor cells
that had CD13 receptors.
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CHAPTER 3. PEPTIDE TARGETING OF PLATINUM ANTICANCER DRUG AND
CURCUMIN USING LHRH MOTIF
3.1 Introduction
Besides cancers of the lung and bronchus, breast and prostate cancers are the most
common causes of cancer deaths among women and men, respectively. With most conventional
drugs and methods of cancer therapy having various side effects, targeted chemotherapy has
become an increasingly popular and efficient way to reduce side effects by improving the
systemic administration of toxic drugs.1, 2 Various studies have found that receptors for certain
peptides and hormones are found in higher concentrations in tumor cells than in normal cells.
Luteinizing hormone-releasing hormone (LHRH), also known as GNRH1, has receptors on
several malignant tissues, including breast, oral, and renal cancers, brain tumors, melanomas, and
liver and prostate cancers.3 Targeting of cancer therapeutics with hormones and hormone analogs
has become a well-established method to generate lower toxicity and more efficient therapies.
Our overall goal is to target tumor cells using a conjugate of LHRH, which has receptors in
various tumor cells, with the anti drugs cisplatin and curcumin. Figure 3.1 shows the final
structures of our target compounds.

Figure 3.1. LHRH conjugates synthesized for this study.
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Besides many hormonally targeted therapeutic agents developed for the treatment of
various tumor cells, Schally et al. have extensively investigated LHRH, and found that the D-lys
moiety offered the most convenient attachment of cytotoxic compounds without changing the
intrinsic high-binding affinity of the peptide to receptors.4-6 Previous studies had shown that
substitution at position 6 of LHRH with a D-amino acid can allow further modification with large
molecules, resulting in potent analogs with very high binding affinities.3 Studies of conjugates of
doxorubicin (DOX) and LHRH allowed the delivery of the cytotoxic DOX directly to the tumor
cells, thereby increasing the concentration of the drug and sparing normal cells unnecessary
exposure.7, 8
Curcumin, a polyphenol known to have antitumor effects, exists in three major
curcuminoids components, which include cyclocurcumin (77%), demethoxycurcumin (17%) and
bisdemethoxycurcumin (3%). Curcumin can exist in enol form or diketo form, with the enol form
being prevalent in solution stemming an important feature on the radical-scavenging ability of
curcumin. Apart from curcumin’s traditional use in foods, mostly in Asia, it has also been used
therapeutically for several ailments, including treatments for respiratory problems, diabetic
wounds, cough, running nose, and abdominal pain; modern scientific research has confirmed its
anti-inflammatory, antitumor, antimicrobial, antioxidant, and antiarthritic effects.9-12 No studies
have shown any toxicity associated with curcumin, irrespective of the concentration.13-15
Several platinum complexes discussed in the previous chapters are used in cancer
chemotherapy; among them are cisplatin and its analogs. Besides the important use of cisplatin,
various side effects make it usage limiting, the most common ones being nausea, nephrotoxity,
vomiting, and neurotoxicity. Further, cancer patients are known to form a resistance to cisplatin,
which is also a major issue. Targeting of cisplatin and its analogs helps to improve not only its
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efficacy but also the therapeutic ratio of platinum agents. Interactions of platinum complexes,
including cisplatin, carboplatin, and dichloro(ethylenediamine)platinum(II), among others, with
DNA helps to arrest the replication and transcription process by being cytotoxic.16,17
We have designed two conjugates. One, a conjugate of curcumin and LHRH (LHRHcurcumin) addresses the hypothesis of whether or not free, diffusible curcumin is required for
optimal anticancer activity. The second conjugate, a conjugate of cisplatin and LHRH, addresses
a similar hypothesis and seeks to ameliorate the systemic side effects that cisplatin and currently
approved tumor drugs have on normal cells. Targeting of cisplatin analogs using CNGRC,
discussed in Chapter 2, has shown that targeted platinum complexes helps to increase specific
damage

to

tumor

cells.

LHRH

was

coupled

with

di-tert-butyl

2-(3-glutaric

aminopropyl)malonate, whose synthesis was reported in Chapter 2. LHRH-malonate allows the
free bidentate carboxylic sites to react with activated cisplatin to form a targeted platinum
complex (LHRH-Pt). With this in mind, we hypothesize that using LHRH, which has receptors
in the tumor cell, is the most efficient way to deliver any chemotherapeutic agents to the tumor,
hence improving the therapeutic ratio.
3.2 Experiment Section
3.2.1 Starting Materials. All starting materials listed below were obtained from commercial
sources and used without further purification: di-tert-butyl malonate, glutaric anhydride
(Aldrich), 3-bromopropyl phthalimide (Fluka). All amino acids and coupling reagents were
obtained from EMD Biosciences.
3.2.2 NMR Spectroscopy. 1H NMR spectra were recorded for solution in CDCl3 on Bruker 400
MHz spectrometers. Peak positions are relative to TMS. All NMR data were processed with
XWIN-NMR and MestRe-C software.
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3.2.3 Peptide Purification and Characterization. All peptides were purified and characterized
using protocols previously described in Chapter 2 unless otherwise stated. HPLC was performed
using a Water 600E multisolvent delivery system with a model 486 tunable detector controlled
by Empower software and Water Deltaprep system, with detection at 220 nm. Different columns
were used for analysis and purification of the peptides. Analytical and semi-preparative
chromatography was performed on a Delta-Pak C4 (5 µm;100 Aº) reverse phase column (8× 100
mm) at 1 mL/min (column 1). Preparative HPLC was performed on Waters Delta-Pak C4 (15
µm;100 Aº) reverse phase column (25 × 100 mm) at 15 mL/min (column 2). Linear gradients of
0.1% aqueous TFA in H2O (Buffer A ) and 0.1% TFA in MeCN (Buffer B ) in all HPLC were
used.
3.2.4 Procedure
3.2.4.1 Synthesis of Curcumin Glutarate Ester (1). Under dry conditions, a solution of
curcumin (0.1 g, 0.271 mmol) in 1 mL of pyridine was allowed to stir at room temperature for 30
min. The solution was treated with glutaric anhydride (0.020 g, 0.180 mmol) and was left to stir
overnight at 60 °C. The solution was concentrated by rotary evaporation, dissolved in CH2Cl2,
and washed with 5% HCl. The organic fraction was dried over MgSO4, and the solvent was
removed by rotary evaporation. The solid product obtained was dried in a desiccator for eight
hours to yield dry curcumin glutarate ester before proceeding to the next step (Scheme 3.2).
Yield, 106 mg (90%). 1H NMR (400 MHz, δ (ppm) in CDCl3):7.61 (m, 2H), 7.16 (m, 5H), 6.94
(m, 1H), 6.53 (m, 2H). 5.83 (m, 2H), 3.95 (s, 3H), 3.87 (s, 3H), 2.70 (t, 2H), 2.56 (t, 2H), 2.11
(m, 2H). TOF-MS (ESI) 483.1657 (M + H+), calculated for C26H26O9 483.16.
3.2.4.2 Synthesis of Di-tert-butyl 2-(3-glutaric aminopropyl)malonate (2). This was
synthesized as described in chapter 2. The yield was 92%. 1H NMR (CDCl3) (ppm): 3.27 (q,
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2H), 3.14 (t, 1H), 2.41 (t, 2H), 2.28 (t, 2H), 1.98 (m, 2H), 1.81(m, 2H), 1.56 (m, 2H), 1.45(s,
18H).

Scheme 3.1. Synthesis of curcumin glutarate ester.
3.2.4.3 Synthesis of LHRH-curcumin (3). LHRH-curcumin peptide was synthesized using
standard Fmoc solid-phase chemistry. H-Rink Amide ChemMatrix resin (Scheme 3.2) (0.52
mmol) was placed in a normal resin column and washed with DMF. The side chain protected
amino acid derivatives used in the sequence were Fmoc-Glu(OtBu)-OH, Fmoc-His(Trt)-OH,
Fmoc-Trp(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-D-Lys(Alloc)-OH, FmocLeu-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, and Boc-Gly-OH. The alloc-protecting group was
removed using Pd(0) followed by double coupling of curcumin glutarate ester. All coupling
utilized four equivalents each of amino acids, malonate, and PyAOP (sometimes HOBT and
TBTU), dissolved in 0.5 M DIEA in DMF at room temperature (with a final concentration of
0.25 M). Washing between reaction times was done using DMF, and coupling involved minimal
preactivation time. Deprotection of the Fmoc group was achieved using 20% piperidine in DMF
for 5 min.
Once the peptide synthesis was complete, a 15 ml cocktail of TFA:phenol:water:TIPS
(88:5:5:2) was added to the resin, and the mixture was agitated for 2.5 hours at room
temperature. The mixture was filtered and the resin washed with TFA (5 mL). The combined
aqueous TFA solutions were extracted with Et2O and then freeze dried. The crude peptide was
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purified by gel filtration to give pure aliquots of LHRH-curcumin. Yield, 0.09 g (36%), ESI-MS
1739.84 (M + Na+), calculated for C85H108N18O21 1717.88.
3.2.4.4 Synthesis of LHRH-malonate. LHRH-malonate was synthesized using standard Fmoc
solid-phase chemistry, as described above. Similar side chain protected amino acid derivatives to
those used in LHRH-curcumin peptide synthesis were used in this sequence. After the allocprotecting group was removed using Pd(0), di-tert-butyl 2-(3-glutaric aminopropyl)malonate was
coupled to the resin, followed by cleavage using the same cocktail cleavage solution described
above. The crude peptide was purified by HPLC, where tR = 25 min; yield, 0.10 g (39%), TOFMS (ESI) 1529.75 (M+H)+, calculated for C70H101N19O20 1529.67.
3.2.4.5 Synthesis of LHRH-Pt (4). LHRH-malonate was dissolved in water, and the pH of the
solution rose to 7 by titration with 1 M solution of NaOH to give neutral LHRH-malonate. The
LHRH-malonate was diluted further using acetonitrile, yielding a solvent ratio of 1:2
(water:acetonitrile).
We prepared cis-[Pt(NH3)2(D2O)2]2+(NO3)2 as described in Chapter 2. An excess of cis[Pt(NH3)2(D2O)2]2+(NO3)2 (2 fold) was reacted with LHRH-malonate solution to give crude
LHRH-Pt conjugate, which was purified by gel filtration on a Sephadex G10 column. ESI-MS
Yield 10% ESI-MS (M + H)2+ Peak at 867.86 calculated for C70H103N21O19Pt 1737.77.
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Scheme 3.2. Synthesis of LHRH-curcumin and LHRH-Pt.
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3.3 Results and Discussion
The peptide LHRH was assembled using general Fmoc chemistry, using the amino acids
described in the synthesis section. Once the peptide was assembled, a catalytic amount of Pd(0)
was used to deprotect the primary amine at the D lysine in the presence of a nucleophile
(morpholine), which mainly acts as a scavenger by capturing the carbocations generated.18,

19

Sodium N,N-diethyldithiocarbamate in DMF was used in the washing step to help remove all of
the palladium. A small amount of resin was cleaved and purified using HPLC and was analyzed
by ESI to confirm the presence of all of the amino acids after removal of all protecting groups.
Figure 3.2 shows the HPLC chromatogram of LHRH, which eluted in 8 min. The mass spectrum
revealed the expected molecular weight with TOF-MS (ESI) (M+H)+ at 1271.63 (Figure 3.3).

Figure 3.2. HPLC chromatogram of LHRH.
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Figure 3.3. Mass spectra of LHRH free peptide.

Taking advantage of the well-established selective reactivity of the phenol group of
curcumin, the reaction of glutaric anhydride with curcumin in the presence of a mild base such as
pyridine gives the curcumin glutarate ester derivative. The 1H NMR (Figure 3.4) and mass
spectrum (Figure 3.5) revealed the formation and presence of the desired compound 1.
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Figure 3.4. 1H NMR of curcumin glutarate ester.
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Figure 3.5. The mass spectrum of curcumin glutarate ester.

Coupling this derivative to [DLys6]-LHRH was done in solid-phase synthesis of the
peptide to give [DLys6]-LHRH-curcumin. The curcumin should be readily released to the site of
action, causing specific vascular damage to the tumor cells. In vivo and in vitro studies of the
conjugate are still ongoing. Figure 3.6 shows the mass spectrum (ESI-MS), revealing the
expected (M+H)+ LHRH-curcumin peak at 1739.84 (M + Na+), calculated for C85H108N18O21
1717.88.
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Figure 3.6. Mass spectra of LHRH-curcumin conjugate.

Coupling of di-tert-butyl 2-(3-glutaric aminopropyl)malonate on the free lysine of LHRH was
achieved with the coupling agent PyAOP using solid-phase synthesis to give the LHRHmalonate. Purification of the peptide gave a single chromatogram of LHRH-malonate, which
eluted in 25 min (Figure 3.7). Analysis by ESI revealed a strong peak at 1529.75 (M+H)+, but the
expected (M+H)+ peak was 1511.65. Without cyclization to form pyroglutamic acid, we
observed a molecular weight which matched the observed molecular weight at 1528.75.
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Figure 3.7. HPLC chromatogram of LHRH-malonate.

Figure 3.8. Mass spectrum of linear LHRH-malonate.
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The dicarboxylic end of LHRH-malonate allows the chelation of the platinum ligand in a
bidentate fashion on the peptide. A mixture of water:acetonitrile (50:50) was used in the
platination step, allowing the solubility of LHRH-malonate at higher pH. On platination,
separation was achieved by gel filtration on Sephadex G10 to give pure aliquots of LHRH-Pt
conjugate; yield 10% (M+2H)2+ peak at 867.86 calculated C70H103N21O19Pt MW = 1737.77. In
vivo and in vitro studies on the conjugate are still ongoing. Figure 3.9, below, shows the mass
spectrum, revealing the expected LHRH-Pt

Figure 3.9. Mass spectrum of LHRH-Pt.
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3.4 Conclusion
We accomplished the synthesis and characterization of LHRH-curcumin and LHRH-Pt, which
are potential targeted antitumor agents. In vitro and in vivo studies are still ongoing.
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CHAPTER 4. EXPLORING WATER SOLUBLE N-TRIDENTATE Pt(II) COMPLEXES
USEFUL FOR SPECTROSCOPIC AND BIOLOGICAL LABELING

4.1 Introduction
The interaction of nucleotides with transition metals, particularly platinum has been
widely reported in recent years; however, with many cellular organelles that can be targeted, the
search for its biological target and mechanism continues.1, 2 Cis-diamminedichloroplatinum(II),
cisplatin, is one of the widely used anticancer drugs. When administered, it can interact with
various cellular components which include glutathione, mitochondria, RNA and DNA, with
DNA generally accepted as the primary target.1, 3-6 The interaction of Pt complexes with mixed
metallothionein and glutathione is believed to be the main cause of resistance and other
shortcomings associated with Pt (II) species.7-9 Interaction of cisplatin with DNA has been
widely studied.1,

10

Cisplatin reacts with DNA by the formation of covalent bonds with N7

purines. It’s interaction with various biological targets and formation of various adducts on
interaction with DNA makes its study too complicated.11, 12
There is need to develop model compounds that have suitable pharmaceutical properties,
are simple and can be monitored spectroscopically to allow further studies on interaction with
DNA. The diethylenetriamine (dien) complex, [Pt(dien)Br]+ and [Pt(dien)Cl]Cl have been
extensively used as monofunctional model compounds to study the binding of metal complexes,
particularly platinum complexes, to DNA and proteins, giving some insight on complicated
reactions formed by bidentate platinum complexes.6,10, 13
Structure-activity study of polyamine analogues reveals that slight structure alteration
causes remarkable changes in their biological activity. N-alkylated polyamines have been found
to alter the neoplastic activity in various human tumor lines.11,
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14

The combination of the

antitumor ligand (polyamine) and the transition metal, Pt(II), with a labeling agent can find
application in many methods in biological research and medical diagnosis. By labeling, we can
analyze the tagged biomolecule and its metabolites in addition to other information about
location, size, amount, and properties of biological systems.15, 16
Our desire for a good spectroscopic probe for studies on the binding of [Pt(dien)X]X-type
complexes

to

biomolecules

has

prompted

us

to

select

N′-[7-(acetamido)-4-

(trifluoromethyl)coumarin]diethylenetriamine (atfcdien) and 2-(bis(2-aminoethyl)amino)acetic
acid (acdien) tridentate ligands for Pt. (Scheme 4.1). These diethylenetriamine derivatives are
simple

with

good

spectroscopic

properties

and

atfcdien

has

the

7-amino-4-

(trifluoromethyl)coumarin (atfc) fluorophore which is fluorescent.
We report the synthesis, and 1H NMR characterization of the N′-[7-(acetamido)-4(trifluoromethyl)coumarin]

diethylenetriamine

(atfcdien)

ligand

(HBr

salt),

2-(bis(2-

aminoethyl)amino)acetic acid (acdien)(Scheme 4.1) and their platinum complexes (Scheme 4.2).
Our synthetic approach gave good yields and a tractable product. We directly prepared and
crystallized

there

water-soluble

[Pt(atfcdien)Br][Pt(Me2SO)Br3]

and

[Pt(acdien)Br]Br

complexes. 1H NMR investigation of the interaction [Pt(acdien)Br]Br with guanosine 5′ monophosphate (5′-GMP) in D2O solution confirmed binding and the presence of one set of 1H
NMR signals implying rapidly inter-converting rotamers. Interaction between [Pt(atfcdien)Br]Br
complex and 5′-GMP gave a Pt(atfcdien)(5′ -GMP) adduct which had two H1′ (5′-GMP moiety)
and two different H5, H6 and H8(coumarin moiety) signals implying slow rate of rotation about
the Pt-N7 bond.
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4.2 Experimental Section
4.2.1 Starting Materials. Diethylenetriamine (dien), bromoacetyl bromide, benzyl 2bromoacetate and 5′-GMP were obtained from Aldrich and atfc was obtained from Lancaster and
used without further purification. N,N′′-bis(tert-butyloxycarbonyl)diethylenetriamine (Bocdien),
7-(bromoacetamido)-4-(trifluoromethyl)coumarin (atfcBr), and cis-Pt(Me2SO)2Cl2 were prepared
by known methods.17-21
4.2.2 Instrumental measurement
4.2.2.1 NMR Spectroscopy. 1H NMR spectra were recorded for solution in DMSO-d6, CDCl3,
and D2O on Bruker 300 MHz, and 400 MHz spectrometers. Peak positions are relative to TMS.
All NMR data were processed with XWINNMR and Mestre-C softwares. For all integrations each
proton is represented as 1H.
4.2.2.2

Fluorescence

Spectroscopy.

DMSO

solutions

(5

μM)

of

7-amino-4-

(trifluoromethyl)coumarin (atfc), 7-(bromoacetamido)-4-(trifluoromethyl)coumarin (atfcBr), N′[7-(acetamido)-4-(trifluoromethyl)coumarin]diethylenetriamine

(atfcdien),

and

the

[Pt(atfcdien)Br]+ cation were prepared for fluorescence studies. The emission spectra were
recorded at the excitation wavelength of 369 nm at 25 °C in 10 mm quartz cuvettes using a Spex
Fluorolog-3 spectrofluorimeter equipped with a 450 W xenon lamp and photomultiplier tube
detector.
4.2.2.3 X-ray Data Collection and Structure Determination. Intensity data were collected for
the four compounds at T=110K, using graphite monochromated MoKα radiation (λ = 0.71073
Å) on a Nonius KappaCCD diffractometer fitted with an Oxford Cryostream cooler. Data
reduction included absorption corrections by the multi-scan method. Crystal data and
experimental details are given in Table 4.2 and 4.3. Structures were solved by direct methods and
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refined by full-matrix least squares, using SHELXL97.22 C-H hydrogen atoms were treated as
riding in idealized positions, with a torsional parameter refined for each methyl group. The N-H
hydrogen atom of atfcBr (2) was refined, and all others were treated as for C-H. One water H
atom for both compound (8) and (9) could not be located. All residual electron density peaks
greater than 1 eÅ-3 were located near heavy-atom positions.
4.2.3 Synthesis
4.2.3.1 N,N′′-bis(tert-butyloxycarbonyl)diethylenetriamine (Bocdien, 1). The Bocdien (1)
ligand was prepared in 50% yield by a known method.19 Briefly, Dry toluene (150 mL), tertbutanol (40 mmol), KOH (1 mmol), and 1,1′-carbonyldiimidazole (40 mmol) were added to a
250 mL round-bottom flask fitted with a dry N inlet and magnetic stirrer and heated to 60 °C
with stirring for 3 h. Dien (20 mmol) was added drop-wise. The solution was left to stir at 60 °C
for a further 3h. The clear mixture was left to cool. The reaction was concentrated in vacuo,
dissolved in CH2Cl2 (100 mL), and washed three times with water (3 X 50 mL). The solution
was dried with anhydrous Na2SO4 and concentrated in vacuo to give colorless oil. 1H NMR
chemical shifts matched the reported values. Colorless needle-shaped crystals of 1•HCl were
obtained by dissolving Bocdien (1) in a equal volume of toluene and dichloromethane and the
solution was allowed to stand at 25 °C for 5 days.
4.2.3.2 7-(Bromoacetamido)-4-(trifluoromethyl)coumarin (atfcBr, 2). AtfcBr (2) was
prepared in 95% yield by a known method.21 Briefly 7- amino-4-(trifluoromethyl)coumarin (0.42
g, 1.0 mmol) was added to an ice-cold solution of 0.2 mL (2.3 mmol) of bromoacetyl bromide in
1 mL of tetrahydrofuran. After 30 min at room temperature, 10 mL of ice water was added. The
product was separated, washed with water, dried, and recrystallized from ethyl acetate. Yellow
blade-shaped crystals were obtained by dissolving atfcBr (2) in ethyl acetate and minimal
amount of hexane and the solution was allowed to stand at 25 °C for 3 days. The measured
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melting point, 200.00 °C, agrees with the reported value. 1H NMR (300 MHz, δ (ppm) in
DMSO-d6): 7.86 (s, 1H), 7.72 (d, 1H), 7.54 (d, 1H), 6.93 (s, 1H), 4.09 (s, 2H), 10.96 (NH).
4.2.3.3 N′-[7-(acetamido)-4-(trifluoromethyl)coumarin]diethylenetriamine (atfcdien, 4). A
solution of Bocdien (1) (1.0 g, 3.3 mmol) in 10 mL of THF-H2O (25:1) was treated with a
solution of atfcBr (2) (0.835 g, 4.8 mmol) and K2CO3 (0.29 g, 2.1 mmol) in 5 mL of THF-H2O
(25:1) and allowed to stir at 25 °C for 12 hours. The solution was concentrated to 5 ml by rotary
evaporation, loaded onto a silica gel column (2 × 19 cm, 100-200 mesh, Davisil, Grade 634,
Type 60A) and eluted with ethylacetate-hexane (2:98) until all of atfcBr (2) was removed. The
product was then eluted with 100% ethyl acetate. Removal of all solvent by rotary evaporation
produced

N,N′′-bis(tert-butyloxycarbonyl)diethylenetriaminly-N′-[7-(acetamido)-4-

(trifluoromethyl)coumarin] (Bocdienatfc) (3) as a yellow solid; yield, 1.21 g, (71%). 1H NMR
(400 MHz, δ (ppm) in DMSO-d6): 7.90 (s, 1H), 7.73 (d, 1H), 7.67 (d, 1H), 6.91 (s, 1H), 3.02 (t,
4H), 2.58 (t, 4H), 3.83 (s, 2H), 1.32 (s, 18H), 10.12 (NH).
A solution of Bocdienatfc (3) (1.06 g, 1.85 mmol) in 10 mL of 30% HBr in acetic acid
was heated at 90 °C for 12 h in a pressure-resistant tube. A light brown solid (atfcdien•3HBr)
was obtained upon cooling the solution at 25 °C, the precipitate was collected by filtration,
washed with ether, and dried under vacuum; yield, 0.79 g (70%). 1H NMR (400 MHz, δ (ppm) in
D2O): 7.81 (s, 1H), 7.79 (d, 2H), 7.42 (d, 1H), 6.87 (s, 1H), 3.58 (s, 2H), 3.10 (t, 4H), 2.94 (t,
4H). ). Anal. Calcd for C16H21F3N4O4: •3HBr: C, 30.35; H, 3.82; N, 8.85. Found: C, 30.07; H,
3.70; N, 8.61.
4.2.3.4 N,N′′-bis(tert-butyloxycarbonyl)diethylenetriaminly-N′-glycine (Bocdienac, 6). Using
the same procedure described for the preparation of 3, a solution of Bocdien (1) was treated with
benzyl

2-bromoacetate

to

obtain

N,N′′-bis(tert-butyloxycarbonyl)diethylenetriaminly-N′-

57

[glycine-benzylester] (Bocdienbz) 5 (Scheme 4.1); yield, 5.46 g, (92%). 1H NMR (400 MHz, δ
(ppm) in D2O): 7.36 (m, 5H), 5.15 (s, 2H), 3.43 (s, 2H), 3.15 (t, 4H), 2.74 (t, 4H), 1.45 (s, 18H).
Bocdienbz (5) (3.45 g, 7.65 mmol) was dissolved in 50 ml EtOH-cyclohexene (2:1). Pd/C
(5%, 1.5 g) was added using additional 50 ml EtOH-cyclohexene (2:1). The mixture was stirred
for 12 h under H2 and then filtered through celite and washed with methanol. The solvent was
removed by rotary evaporation to yield an off-white solid which was crystallized from
MeOH/Ether. The solid obtained was washed with ether and air dried to give Bocdienac (6);
yield, 2.62 g (95%) 1H NMR (400 MHz, δ (ppm) in CDCl3): 1.47 (s, 18H), 3.41 (t, 4H), 3.51 (t,
4H), 3.80 (s, 2H). Anal. Calcd for C16H31N4O6: C, 53.17; H, 8.65; N, 11.63. Found: C, 53.02; H,
8.63; N, 11.45.

Scheme 4.1. Synthesis of atfcdien and acdien. Reagents and conditions: (i) 2, THF, H2O, K2CO3
25 °C, 12 h; (ii) 30% HBr in acetic acid; (iii) benzyl 2-bromoacetate, THF, H2O, K2CO3; (iv)
cyclohexene, MeOH, Pd/c, H2.
4.2.3.5 2-(Bis(2-aminoethyl)amino)acetic acid (acdien•3HBr, 7). Bocdienac (6) (Scheme 4.1)
was

deprotected

using

the

procedure

for

atfcdien•3HBr

(4)

to

give

2-(bis(2-

aminoethyl)amino)acetic acid (acdien•3HBr) 7; yield, 0.67 g (90%). Briefly, a solution of
Bocdienac (6) (0.66 g, 1.85 mmol) in 10 mL of 30% HBr in acetic acid was heated at 90 °C for
12 h in a pressure-resistant tube. A light yellow solid (acdien•3HBr) was obtained upon cooling
the solution at 25 °C, the precipitate was collected by filtration, washed with ether, and dried
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under vacuum. 1H NMR (400 MHz, δ (ppm) in D2O): 3.01 (t, 4H), 3.15 (t, 4H), 3.56 (s, 2H).
Anal. Calcd for C6H18N3O2•3HBr•H2O: C, 17.08; H, 4.78; N, 9.96. Found: C, 17.20; H, 4.82; N,
9.90.
4.2.3.6 [Pt(atfcdien)Br][Pt(Me2SO)Br3]. A solution of atfcdien•3HBr (4) (31.1 mg, 0.049
mmol) in 1 mL of H2O was neutralized by the addition of aqueous KOH (8.2 mg in 0.5 mL),
under stirring to give the free amine. cis-Pt(Me2SO)2Cl2 (20.6 mg, 0.049 mmol) was suspended
in 10 mL of acetone with stirring. The solution of the free amine was added drop wise to the cisPt(Me2SO)2Cl2 suspension, and a bright yellow solution was obtained. The yellow solution was
stirred overnight and then reduced to ~2 mL under vacuum. The yellow precipitate,
[Pt(atfcdien)Br]Br formed was collected by filtration and the clear filtrate upon keeping at 5 °C
for 2 weeks gave orange plate like crystals of [Pt(atfcdien)Br][Pt(Me2SO)Br3] (Scheme 4.2). 1H
NMR of the yellow powder [Pt(atfcdien)Br]Br and [Pt(atfcdien)Br][Pt(Me2SO)Br3] were similar;
yield for [Pt(atfcdien)Br][Pt(Me2SO)Br3] (8a): 10 mg, (35%); yield for [Pt(atfcdien)Br]Br(8b):
10.6 mg, (30%) 1H NMR (400 MHz, δ (ppm) in DMSO-d6): 7.92 (s, 1H), 7.78 (d, 1H), 7.57 (d,
1H), 7.02 (s, 1H), 4.45 (s, 2H), 5.79 (NH), 5.48 (NH), 3.47-2.97(br m, 8H, CH2). Anal. Calcd for
C18H25Br4F3N4O4Pt2S•CH3COCH3•H2O: C, 20.40; H, 2.69; N, 4.53. Found: C, 20.45; H, 2.46;
N, 4.83.
4.2.3.7 [Pt(acdien)Br]Br (9a). [Pt(acdien)Br]Br was synthesized and crystallized as a
monohydrate

using

the

experimental

procedure

described

in

the

synthesis

of

[Pt(atfcdien)Br][Pt(Me2SO)Br3]; yield 18 mg, (75%). 1H NMR (400 MHz, δ (ppm) in D2O): 5.42
(br s, NH), 4.97 (br s, NH), 4.29 (d, 2H), 3.65-2.99 (br m, 8H, CH2). Anal. Calcd for
C6H15Br2N3O2Pt•0.5CH3OH: C, 14.67; H, 3.22; N, 7.90. Found: C, 14.51; H, 3.03; N, 7.99.
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4.2.3.8 [Pt(acdien)Cl]Cl (9b). 4 M HCl in dioxane was used for the deprotection of Bocdienac
as described in the experimental procedure for the synthesis of atfcdien•3HBr (4) to give an off
white solid of atfcdien•3HCl. Briefly, a solution of Bocdienac (6) (1.00 g, 2.77 mmol) in 10 mL
of 4 M HCl in dioxane was heated at 90 °C for 12 h in a pressure-resistant tube. A white solid
was obtained upon cooling the solution at 25 °C, the precipitate was collected by filtration,
washed with ether, and dried under vacuum to give acdien•3HCl; yield 0.37 mg, (50%). This was
further

treated

with

cis-Pt(Me2SO)2Cl2

as

described

in

the

synthesis

of

Pt(atfcdien)Br][Pt(Me2SO)Br3] to give [Pt(atfcdien)Cl]Cl; yield 20 mg, (78%). 1H NMR (400
MHz, δ (ppm) in D2O): 5.42 (br s, NH), 4.97 (br s, NH), 4.26 (d, 2H), 3.73-3.15 (br m, 8H, CH2).
Anal. Calcd for C6H15Cl2N3O2Pt: C, 16.87; H, 3.54; N, 9.84. Found: C, 17.00; H, 3.76; N, 9.63.

Scheme 4.2. Synthesis of [Pt(atfcdien)Br]+ and [Pt(acdien)Br]+. Reagents and conditions: (v) 4,
acetone, H2O, KOH; (vi) 7, acetone, H2O, KOH.
4.2.3.9 Formation of Pt(acdien)(5
′ -GMP) and Pt(atfcdien)(5′-GMP). A solution of
Pt(acdien)(5′-GMP) and Pt(atfcdien)(5′-GMP) was prepared by treatment of [Pt(acdien)Br]Br
and [Pt(atfcdien)Br]Br (5 mM) respectively in D2O (600 µL) with 5′-GMP in a stoichiometric
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amount at pH = 4.2. The solution was maintained at 25 °C and monitored by 1H NMR
spectroscopy until no change in signal intensity was observed. DNO3 and NaOD solutions (0.1
M in D2O) were used to adjust the pH of D2O solutions directly in the NMR tube when
necessary.
4.3 Results and Discussion
4.3.1 Atfcdien and Acdien Synthesis. The general strategy of the synthesis of atfcdien and
acdien is shown in Scheme 4.1. Synthesis of Bocdien and atfcBr provide us with universal
starting materials for all the subsequent syntheses. AtfcBr was first reported by Bissell et al.21
and was characterized by melting point only. In addition to the melting point, we were able to
crystallize the product (Figure 4.1) and characterize by 1H NMR spectroscopy.

Figure 4.1 Ortep rendering of the structure of atfcBr (2) (50% probability ellipsoids).
The synthesis of Bocdien was reported by Rannard et al.19 Selective protection of the primary
amines allow as to put desirable function on the secondary amine. Beside high yields being
reported by Rannard group (95%), we were only able to obtain 50% yield (Figure 4.2).
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Figure 4.2. Ortep rendering of the structure of Bocdien (1) (50% probability ellipsoids).
AtfcBr was treated with Bocdien to give Bocdienatfc by alkylation of the secondary amine by
using K2CO3 base. Similar procedure was used in the alkylation of the secondary amine using
benzyl 2-bromoacetate. Due to the difficulty in separating modified and unmodified protected
dien, an excess of the benzyl 2-bromoacetate and atfcBr was used in the alkylation reaction to
increase the yield and simplify the purification process. Efficient deprotection of the Z-group in
Bocdienbz ligand was achieved by applying Pd/C which resulted in Bocdienac (95%) yield. This
was followed by another deprotection of tert-butyloxycarbonyl group (Boc) on the primary
amine in Bocdienatfc and Bocdienac ligands. By using the 30% HBr in acetic acid mixture the
Boc group was efficiently removed to give atfcdien•3HBr (70%) and acdien•3HBr (90%).23-25
This specific procedure has been successfully applied in deprotection of the tosyl group from
dien-type ligand by Carlone et al. (unpublished results). Removal of the Boc group can also be
achieved by using 4 M HCl in dioxane mixture to give HCl salts of the free primary amines. The
chemical shifts of the ligands 2, 3, 4, and 8 are listed in Table 4.1 (See Figure 4.4 for
numbering).
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Table 4.1. 1H NMR Chemical Shifts (ppm) in DMSO-d6 for species containing atfc
H5
7.35
7.54
7.67
7.61

H6
6.66
7.72
7.73
7.68

H8
6.51
7.86
7.90
7.98

N'H

Atfc
atfcBr
Bocdienatfc
Atfcdien

H3
6.44
6.93
6.91
6.94

[Pt(atfcdien)Br]Br

7.02

7.57

7.78

7.92

[Pt(atfcdien)Me2SO]Br+

7.04

[Pt(atfcdien)Br][Pt(Me2SO)Br3]

7.02

[Pt(atfcdien)Me2SO][Pt(Me2SO)Br3]

7.04

7.95
7.57

7.78

7.92
7.95

N"H
6.52
10.96
10.12
10.50

H12

5.48
5.79
6.24
6.40

10.99

4.45

5.48
5.79
6.24
6.40

10.99

4.45

6.88
7.68

Figure 4.3. Ortep rendering of the structure of [Pt(atfcdien)Br][Pt(Me2SO)Br3] (8a) (50%
probability ellipsoids).
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4.09
3.83
3.53

4.3.2 [Pt(atfcdien)Br][Pt(Me2SO)Br3]. The reaction between atfcdien and cis-Pt(Me2SO)2Cl2
gave orange crystals of [Pt(atfcdien)Br][Pt(Me2SO)Br3]•H2O (Figure 4.3) after filtration of
[Pt(atfcdien)Br]Br precipitate and the clear filtrate was kept at 5 °C for 2 weeks. Soon after 8a
was dissolved in DMSO-d6 the 1H NMR spectrum in DMSO-d6 (Figure 4.4) showed the presence
of two species, which were assigned to the [Pt(atfcdien)Br][Pt(Me2SO)Br3] (70%) and
[Pt(atfcdien)Me2SO][Pt(Me2SO)Br3] (30%). The minor downfield set was assigned to the
solvolysis

product

Pt(atfcdien)(Me2SO)]2+.

Presence

of

the

solvated

species

[Pt(atfcdien)Me2SO]2+ was confirmed by addition of [Et4N]Br to the solution where the signals
of [Pt(atfcdien)(Me2SO)]2+ disappeared and [Pt(atfcdien)Br]+ signals increased in size (not
shown). The NMR data is summarized in Table 4.1. The 1H NMR aromatic signals of
[Pt(atfcdien)Br][Pt(Me2SO)Br3] in DMSO-d6 compared to atfcdien•3HBr were also not
significantly affected by the binding of Pt to atfcdien•3HBr ligand. Once the ligand binds to Pt
through N′H (See Figure 4.4 for numbering), the amine signals appeared which we attributed to
slower NH exchange for the coordinated ligand. Because of the size of the [Pt(atfcdien)Br]+
cation, a large [Pt(Me2SO)Br3]- counterion favored the formation of crystals. Formation of a
similar counterion ([Pt(Me2SO)Cl3]-), was reported by Veldman et al.26
4.3.3 [Pt(atfcdien)Br]Br. As described above, the reaction between atfcdien and cisPt(Me2SO)2Cl2 gave [Pt(atfcdien)Br]Br as a yellow powder. Similarly one major and one minor
set of NH signals were observed on dissolving 8b in DMSO-d6. The two species were assigned
to the [Pt(atfcdien)Br]Br (70%) and a downfield set of [Pt(atfcdien)(Me2SO)]Br+ (30%) and
similarly confirmed by addition of [Et4N]Br. No significant difference was observed between
[Pt(atfcdien)Br]Br and [Pt(atfcdien)Br][Pt(Me2SO)Br3] for both aromatic signals and NH
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signals. The 1H NMR spectrum of yellow powder [Pt(atfcdien)Br]Br had similar chemical shifts
as that of [Pt(atfcdien)Br][Pt(Me2SO)Br3].

Figure 4.4. 1H NMR spectrum in DMSO-d6
[Pt(atfcdien)(Me2SO)]2+ for peaks labeled with *.

(ppm)

of

[Pt(atfcdien)Br]+

Figure 4.5. Fluorescence emission spectrum of atfc derivatives solutions ( 5 µM, DMSO).
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and

Figure 4.5 shows the emission spectra of atfc, atfcBr, atfcdien and [Pt(atfcdien)Br][X]. The
fluorescence intensity of coumarin was quenched by 90% after addition of Pt(II). AtfcBr ligand
emission intensity was significantly quenched when compared to that of the original atfc ligand
due to the formation of the acetyl bromide bond. Substitution at position 7 with a group that has
an electron withdrawing effect is known to weaken the fluorescence intensity.27 The presence of
electron withdrawing groups like carbonyl group attached to the primary amine of atfc pumps
electrons out of the atfc ring also contributing to the quenching effect. In addition to an electron
withdrawing effect, the presence of bromide atom in the atfcBr contributes to about 30%
decrease in fluorescence intensity. Addition of more bromide atoms on the ligands increases the
quenching effect. This is illustrated by atfcdien which has 3HBr salts causing a dramatic
decrease of fluorescence intensity to about 10%. The fluorescence intensity of [Pt(atfcdien)Br]X
decreases further with the presence of the platinum metal. The presence Pt(II) and Br atoms
changes the electronic properties of the fluorophore, enhancing the spin forbidden process
therefore we attribute the significant decrease in fluorescence to the “heavy atom effect”.28-32

Figure 4.6. Ortep rendering of the structure of [Pt(acdien)Br][Br] (9) (50% probability
ellipsoids).
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4.3.4 [Pt(acdien)Br]Br. The reaction between acdien•3HBr and cis-Pt(Me2SO)2Cl2 gave
colorless crystals of [Pt(acdien)Br][Br] (Figure 4.6) and a non-crystalline yellow powder. The
yellow precipitate was collected by filtration and recrystallized further using methanol to give
pure [Pt(acdien)Br]Br confirmed by 1H NMR (Figure 4.7) and elemental analysis. The acdien
ligand is bound to Pt(II) in a tridentate fashion. Broad signals were observed for the dien region
which integrated to 8H as expected and a singlet was observed for the hydrogen of the α carbon
next to the carboxylic moiety. The two different signals observed for the NH were attributed to
the magnetically in equivalent set of hydrogen.
Immediately upon dissolution of 9a the 1H NMR spectrum in DMSO-d6 showed the presence
of two sets of NH signals which were assigned to the [Pt(acdien)Br]Br (> 90%) and
[Pt(acdien)(Me2SO)]Br species (<10%). Dissolution of 9a in D2O showed the presence of one
sets of NH signals which were assigned to the [Pt(acdien)Br]Br species. We attribute the
presence of the NH signals in D2O to be due to the acid nature of D2O solvent used in the NMR
analysis.

Figure 4.7. 1H NMR spectrum in 400 MHz D2O (ppm) for [Pt(acdien)Br]Br.
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4.3.5 [Pt(acdien)Cl]Cl. Pt(acdien)Cl]Cl was prepared by treating cis-Pt(Me2SO)2Cl2 with
atfcdien•3HCl. Atfcdien•3HCl was made by deprotecting Bocdienac with 4 M HCl in dioxane.
Similar deprotection method has been report by Han et al.33 Dissolution of 9b in D2O or DMSOd6 showed the presence of one sets of NH signals which were assigned to the [Pt(acdien)Cl]Cl in
both cases. Characterization results for both the Pt(acdien)Cl]Cl and [Pt(acdien)Br]Br were very
closely related, however; Pt(acdien)Cl]Cl was very hygroscopic and it required careful handling.
Similar hygroscopic compounds have been synthesized before including [Pt(dien)Cl]Cl.34, 35

Figure 4.8. Two possible rotamers of Pt(acdien)(5′-GMP) and Pt(atfcdien)(5′-GMP) adducts
where R is acOH or CH2COatfc groups.
4.3.6 Pt(acdien)(5′-GMP).The 1H NMR spectrum of Pt(acdien)(5′-GMP) adduct at equilibrium
(pH= 4.2) had one H8 and one H1′ signals that each integrated to one proton. The 1H NMR
signals of the free 5′-GMP were upfield compared to the signals of Pt(acdien)(5′-GMP) adduct.
The product H8 signal (Figure 4.9) at 8.56 ppm shifted downfield by ca. 0.4 ppm compared to
that of the H8 signal of the free 5′-GMP (8.15 ppm) as a result of the binding of ′5 -GMP to Pt
through N7.36, 37 The product H1′ signal at 5.78 ppm shifted downfield compared to that of the
H1′ signal of the free 5′-GMP at 6.01 ppm. Christoforou et al. also observed similar results with
Pt(DNSH-dien)(5′-GMP) where single signals for both H1′ and H8 were observed irrespective of
the possession of unsymmetrical carrier ligand on the tridentate dien-type ligand (DNSH=5-
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(dimethylamino)naphthalene-1-sulfonamide).38

Other

studies

on

Pt(N-Me3dien)(5′-GMP)

showed temperature dependence would allow the formation of more than one rotamer.39
Beside lack of steric hindrance at the terminals N-H of the dien, we suggest that the
presence of -CH2CO2H moiety of the acdien is a significantly better hydrogen-bond donor than
the -CH2 (hindered amide) moiety of atfcdien, then the carboxylic acid could speed up the Pt-N
bond rotation through hydrogen-bonding to the carboxylic acid in a quasi-stable intermediate
halfway between the two possible double N-H hydrogen-bonded rotamers. The presence of one
pair of signals for the protons suggests that the adduct formed has a rate of rotation about the Pt–
N(7) bond that is too rapid (Figure 4.8) for the observation of a set of signals for each possible
rotamer.37, 40

30 min after mixing

2 days after mixing

Figure 4.9. 1H NMR of Pt(acdien)(5′-GMP) (400 MHz) in D2O at 25 °C.
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4.3.7 Pt(atfcdien)(5
′ -GMP). The reaction between the [Pt(atfcdien)Br]Br complex and
guanosine 5′ -monophosphate (5′ -GMP) gave a Pt(atfcdien)(5′ -GMP) adduct which had one H8
and two H1′ signal that integrated to one proton each. In the aromatic region the signal at 8.64
ppm, assigned to the [Pt(atfcdien)(5′-GMP) H8, is shifted downfield by ca. 0.5 ppm with respect
to the free 5′-GMP H8 signal (at 8.13 ppm), characteristic of N7 binding.36, 37 A downfield shift
was also observed for the H1′ sugar proton signals (Figure 4.12). The 1H NMR spectrum of the
Pt(atfcdien)(5′-GMP) at higher field (700 mHz) permitted observation of both the signal for H1′
and some atfc minor rotamer with more clarity (Figure 4.13). Similar results were observed for
Me3dienPt(5′-GMP) which has both terminal primary amines substituted with methyl group
(Figure 4.10), where two H8 signals were observed indicating the formation of two rotamers due
slow rotation about the Pt–N(7) bond attributed to steric hindrance from the presence of the
methyl groups. 13,36, 41

Figure 4.10. Two perpendicular rotamers of Me3dienPt(5′-GMP).
In our case it seems unlikely that the free amine end would cause any steric hindrance. We see
two different H1′ and two different signals for H5, H6 and H8 of the atfc (see table 4.4 for
numbering) suggesting we have two rotamers. We suggest that the planar conformer indicated in
Figure 4.11 is more stable due to hydrogen bonding than the perpendicular conformer in figure
4.8. The formation of this planar conformer might allow the rate of rotation about the Pt–N7

70

bond to be relatively slow enough to allow the observation of more signals due to rotamer,
however; more study need to be done to confirm this hypothesis.

Figure 4.11. Two possible planar rotamers of Pt(atfcdien)(5′-GMP).

30 mins after mixing

7 days after mixing

Figure 4.12. 1H NMR spectrum (400 MHz) in D2O of Pt(atfcdien)(5′-GMP) at 25° C.
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7 days after mixing

Figure 4.13. 1H NMR spectrum (700 MHz) in D2O of Pt(atfcdien)(5′-GMP) at 25 °C.
4.3.9 X-ray Crystallographic Structural Studies.
4.3.9.1 Bocdien (1). Both cation and chloride ion lie on crystallographic C2 axes and are
illustrated in Figure 4.2. The N(CH2)2NH2(CH2)2N chain is fully extended, with torsion angles
178.6(7)˚ about N1-C1 and 176.6(5)˚ about C1 -C2. However, the Boc moieties are folded away
from this line, with C1-C2-N2-C3 torsion angle 84.4(8)
˚. The central ammonium forms
hydrogen bonds to chloride (N…Cl 3.122(6) Å), and the Boc NH group forms N2-H…O2
intermolecular hydrogen bonds with distance 2.874(8) Å.
4.3.9.2 atfcBr (2). The 11-atom atfc ring system is coplanar to within a maximum deviation of
0.021(2) Å (for C2), and the NHCOCH2 group also lies nearly in this plane. The C8-C7-N1-C11
torsion angle is -2.1(3)˚, and the C7-N1-C11-C12 torsion angle is 178.20(18)˚. The amide N -H
group forms an intermolecular hydrogen bond with the atfc carbonyl oxygen atom, N1-H…O2
(at 3/2+x, 3/2-y, 1/2+z) distance 2.871(2) Å and angle about H 168(2)
˚ as illustrated in
4.1.
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Figure

Table 4.2. Crystal data, data collection and refinement parameters.
Compound
CCDC
no.

Bocdien.HCl 1

deposit 663056

atfcBr 2

[Pt(atfcdien)Br][Pt(
Me2SO)Br3] 8

[Pt(acdien)Br]Br 9

663057

663058

663059

Pt(tmbSO2-N,NMe2dien)Cl 10

Formula

[C14H30N3O4] Cl

C12H7BrF3NO3

[C16H19BrF3N4O3Pt
][C2H6Br3OPtS]•H2
O

[C6H15BrN3O2Pt]B
r•H2O

C15H26ClN3O2PtS

Formula weight

339.86

350.1

1178.32

534.14

542.99

Space group

Pccn

P21/n

P-1

P-1

P21/c

Temp., K

110

110

110

110

90

a, Å

34.40(4)

4.4945(10)

8.1663(10)

6.7892(10)

15.075 (3)

b, Å

5.069(5)

24.582(4)

8.3103(10)

8.2078(15)

13.191 (3)

c, Å

10.888(10)

10.978(2)

22.631(3)

11.583(2)

9.6030 (15)

β, deg.

90

99.197(8)

87.098(6)

78.924(9)

105.167(13)

Cell volume, Å3

1899(3)

1197.3(4)

1391.5(3)

624.80(18)

1843.1(6)

Formula
units/unit cell

4

4

2

2

4

Dcalc, g cm-3

1.189

1.942

2.812

2.839

1.957

Rint

0.091

0.02

0.035

0.030

0.057

Independent
reflections

1193

2730

6152

4874

6660

R (obs)

0.092

0.026

0.042

0.033

0.044

Rw, F2(all data)

0.245

0.053

0.118

0.077

0.093

GOF

1.11

1.04

1.04

1.06

1.03

Max
resid.
Peaks (eÅ-3)

0.66, -0.30

0.38, -0.36

2.70, -3.84

1.98, -2.06

4.01, –2.09

a

R = (Σ||Fο| - |Fc||)/Σ|Fο|; bwR2 = [Σ[w(Fο2 - Fc2)2]/Σ[w(Fο2)2]]1/2

4.3.9.3 [Pt(atfcdien)Br][Pt(Me2SO)Br3] (8a). This salt crystallizes as the monohydrate (H2O
not shown in Fig. 3). The anion has Pt-Br distances in the range of 2.4161(11) - 2.4371(11) Å
and Pt-S distance of 2.219(2) Å. While we find no other salts of the [Pt(Me2SO)Br3]- anion in the
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Cambridge database, it contains a number of salts of [Pt(Me2SO)Cl3]-, most of which have Pt(II)containing cations, e.g. [Pt2(terpy)2Cl2] [Pt(Me2SO)Cl3].42 In the cation, the three Pt-N distances
are statistically indistinguishable, within the range of 2.031(7) - 2.044(7) Å, while the Pt-Br
distance is 2.4058(11) Å. The coordination geometry of the cation is slightly pyramidallydistorted square planar, with Pt1 lying 0.1005(5) Å out of the N3Br plane. Cations and anions
alternate in stacks with Pt1…Pt2 distances 3.987(1) and 4.432(1) Å and a dihedral angle of
17.8(3)˚ between their anion coordination planes. The conformation of the atfc-amide side chain
is similar to that seen in atfcBr (1), with the torsion angle about C7-N4 3.3(15)˚ and that about
N4-C6 173.4(8)˚.
Cini and coworkers42 discussed extensively the [Pt(Me2SO)Cl3]- torsional angles, which are
different from those in 8a. This deviation is attributed to difference between the Br group
attached to the platinum counter ion complex compare to the chloride group attached to their
complex. In the bromo compound, a methyl group is nearly eclipsed with the Br, with a torsional
angle Br4 Pt2 S1 C18 -2.1(4) which is smaller than the reported torsional angle. In the chloro
complex42, the S=O is nearly eclipsed with Cl, having Cl-Pt-S-O torsional angle as 3.1(6)
˚.
However aside from the differences in Pt-Cl vs Pt-Br distance there is little structural difference
between [Pt(Me2SO)Br3]- and [Pt(Me2SO)Cl3]-.
4.3.9.4 [Pt(acdien)Br]Br (9). The Pt-Br distance is 2.4055(7)Å, and the Pt-N distances are equal
within experimental error, falling within the range of 2.035(4) - 2.050(4)Å. The coordination
plane is slightly nonplanar, with a slight folding along the central axis. Thus, N1 and N3 both lie
0.061(2)Å out of the N3PtBr best plane, while N2, Pt1, and Br1 lie 0.041(2), 0.0550(14), and
0.0266(15)Å out of plane, respectively, on the opposite side. So, the N1/N2/Pt/Br plane forms a
dihedral angle of 5.79(5)˚ with the N3/N2/Pt/Br plane. The carboxyl group forms a hydrogen
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bond to the bromide ion, with O…Br distance 3.133(4)Å and ˚ 173
angle abou

t H. All NH2

hydrogen atoms are involved in intermolecular hydrogen bonds to bromide, coordinated bromo,
and

carboxyl

O2.

Both

platinum

complexes

[Pt(atfcdien)Br][Pt(Me2SO)Br3]

and

[Pt(atfcdien)Br]Br have comparable N-Pt-Br bond distances showing little influence of ligands
attached to the tertiary N hence no trans influence.
Table 4.3. Selected Bond distances (Ao) and Angle (deg) for [Pt(atfcdien)Br][Pt(Me2SO)Br3] (8)
and [Pt(acdien)Br]Br (9).
Bond Distances
Pt1- N1
Pt1- N2
Pt1- N3
Pt1- Br1
Pt2- S1
Pt2- Br2
Pt2- Br3
Pt2- Br4
S1- O4
S1- C17
S1- C18

8

9

2.031(7)
2.044(7)
2.039(8)
2.4058(11)
2.219(2)
2.4161(11)
2.4234(12)
2.4371(11)
1.486(7)
1.771(11)
1.768(11)

2.047(4)
2.050(4)
2.035(4)
2.4055(7)

170.1(3)
85.8(3)
85.7(3)
94.2(2)
174.7(2)
93.9(2)
177.09(7)
87.79(7)
89.30(4)
94.33(7)
177.61(4)
88.58(4)

168.96(17)
85.21(16)
85.85(17)
95.21(12)
178.82(11)
93.60(14)

Bond Angles
N1- Pt1- N3
N1- Pt1- N2
N2- Pt1- N3
N1- Pt1- Br1/Cl1
N2- Pt1- Br1/Cl1
N3- Pt1- Br1/Cl1
S1- Pt2 Br3
S1- Pt2- Br2
Br2 Pt2- Br3
S1- Pt2- Br4
Br2- Pt2- Br4
Br3- Pt2- Br4
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4.4 Conclusion
Complexes 8a, 8b, 9a and 9b are bound in a tridentate fashion, evidence being the two NH1
signals indicative of H atoms attached to the N that are chemically different in space but equal
for both terminal NH1 giving the two signals. In DMSO-d6, Br and Cl ligands are slowly
displaced giving rise to minimal solvated species for each platinum complex. Similar behavior
has been reported for [Pt(DNSH-tren)Cl]Cl by Christoforou et al.38 Immediately on dissolution
in DMSO-d6, [Pt(DNSH-tren)Cl]Cl showed two sets of NH NMR signals. The upfield set was
assigned to [Pt(DNSH-tren)Cl]Cl and the downfield was assigned to [Pt(DNSH-tren) Me2SOd6]2+. Our finding on minimal solvolysis of [Pt(atfcdien)Br]X agree with their findings
confirming that the presence of the alkyl group in the central N decreases DMSO-d6 solvolysis.
We

accomplished

the

synthesis

and

solution

characterization

of

[Pt(atfcdien)Br][Pt(Me2SO)Br3], Pt(atfcdien)Br]Br, [Pt(acdien)Br]Br and [Pt(acdien)Cl]Cl
complexes by employing various synthetic steps. Complexes 8 and 9 offer various advantages
for their use as biological probes. The presence of atfc groups on the carrier ligand introduces the
fluorescence property to the ligand, which would allows us to monitor and study the ligand
interaction with biological molecules by spectroscopic techniques, however; due to the decrease
fluorescence intensity no much fluorescence information could be obtained from the model
ligand. The carboxylate groups allow studying of the monofunctional Pt complex
spectroscopically by giving a simple spectrum that can be followed and studied by NMR. Also
the solubility of both Pt complexes in water allows aqueous solution studies under physiological
conditions, both with nucleotides and other biological molecules. These new complexes have
desirable features for assessing the potential of tridentate platinum complexes for investigating
selective monocoordination of metal complexes to DNA and to peptides.
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CHAPTER 5. CONCLUSIONS
This dissertation has focused on design, synthesis, and structural analysis of short
targeting peptides conjugated to conversational drugs and synthesis of small platinum
complexes. Two targeting sequences used were, LHRH and CNGRC both of which have
receptors in the tumor cells. Development of new strategies to overcome the side effects
associated with current cancer drugs is significant in drug development. Synthesis of targeted
anticancer drugs and study of their biological properties is crucial for potential therapeutic agent
development.
Chapter 2 of this dissertation describes the synthesis of targeted platinum complexes
using CNGRC sequence. Based on the fact the CNGRC sequence have been successful used to
target tumor cell, two platinum complexes were designed where minipeg group was placed on
each side of the sequence to enhance on solubility. A malonoly linker was synthesized to
improve on the spacing and provided a terminus for platination. The biological data of the final
complex revealed that targeted platinum complexes were more effective at suppressing
proliferation of prostate tumor cells that had CD13 receptors and had low toxicity to tumor cell
that had no receptors compared to free carboplatin drug tested.
Chapter 3 describes the synthesis of targeted curcumin and platinum complexes using the
LHRH sequence. Curcumin possesses hydroxide groups which can be readily alkylated under
mild basic conditions. The assembly of the LHRH-curcumin peptide was by solid phase
synthesis. Similarly the LHRH-malonate synthesis was achieved by solid phase synthesis
followed by platination using solution phase synthesis to give LHRH-Pt. Biological studies on
these structures are still ongoing.
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Chapter 4 of this dissertation addresses the synthesis of small platinum complexes and
their application as potential biological labeling probes. The presence of atfc groups on the
carrier ligand introduces the fluorescence property in the ligand, which allows us to monitor and
study the ligand interaction with DNA by spectroscopic techniques. The platinum complexes
have desirable features for assessing the potential of tridentate platinum complexes for
investigating selective monocoordination of metal complexes to DNA and to peptides.
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APPENDIX A. ONGOING WORK AND FUTURE STUDIES
A.1 Synthesis of Targeted Phthalocyanines
Phthalocyanine and related compounds like porphyrins, have been the subject of intense
interest due to their biological importance and their physical, chemical, and spectroscopic
properties.1 A phthalocyanine is a macrocyclic compound which absorbs light at high
wavelength around 650-800 nm in comparison to porphyrin giving a bigger optical window
necessary for photodynamic therapy (PDT) application. PDT involves combination of light and
photosensitizer to affect biological outcome. The cytotoxic effect of PDT is caused by interaction
of photosensitizer’s excited states with endogenous oxygen in the target cell.2, 3
Although phthalocyanines are effective class of photosensitizers, they have been
identified with major disadvantages that impact their effectiveness in PDT. An example is lack
of cellular localization and cytotoxicity where the mechanism of their localization is still vague.4
Our overall goal is to target phthalocyanine PDT agents to tumor cells using CNGRC and
LHRH sequence as described before in the earlier chapters
A.2 Results
Scheme A.1 show one of the proposed and attempted synthesis of CNGRCPhythalocynine conjugate. The Pythalocynine on resin was synthesized by Sibel Edem. Addition
of amino acids on the resin was achieved using solid phase chemistry and the linear CNGRC –
phythalocynine conjugate was confirmed by mass spectra (Maldi) where M +H peak was
2290.37 calculated C102H138N24O29S2Zn 2291.88. Cyclization of the CNGRC –phythalocynine
was not successful.

Scheme A.2 shows ongoing synthesis of phthalocyanine with LHRH

pentynoic acid. The LHRH-pentynoic was confirmed to have the expected M +H peak 1350.70
calculated for C64H90N18O15 1350.68. The phthalocyanine in this scheme was synthesized by
Mercy Mudyiwa.
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Scheme A.1. Synthesis of CNGRC-phthalocyanine (Conjugate 1) where R= (CH2CH2O)3CH3
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Scheme A.2. Synthesis of LHRH-phthalocyanine (Conjugate 2)
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APPENDIX B. SUPPLEMENTARY MATERIAL FOR CHAPTER 2

Figure B.1. Fluorescence microscopy of cells that have been treated with various compounds,
incubated for 48 h at 37°C and then imaged by JC-1 staining after a further 30 min of incubation.
Images A and D; PC-3 and LNcap cells, respectively, treated with RPMI media only. Images B
and E; PC-3 and LNcap cells, respectively, treated with 200 µM of Pt-peptide conjugate 7 in
RPMI media. Images C and F; PC-3 and LNcap cells, respectively, treated with 50% DMSO.
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Figure B.2. The effect of carboplatin, cyclic mPeg-CNGRC-mal (6 free peptide), the mixture of
carboplatin and mPeg-CNGRC (9), and the Pt-peptide conjugates; cyclic mPeg-CNGRC-Pt (7)
and cyclic mPeg-CNGRC-Pten (8) on the proliferation of prostate cancer PC-3 (CD13 positive)
cells and LNcap (CD13 negative) cells. (A) PC-3 cells and (B) LNcap cells were exposed to the
compounds listed and incubated for 4 h followed by replacement of the drug medium with the
regular cell growth medium and incubation for 48 h at different concentration.
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Figure B.3. The structure of di-tert-butyl 2-(3-phthalimidopropyl)malonate with 50% probability
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Figure B.4. 1H NMR of Di-tert-butyl 2-(3-glutaricaminopropyl)malonate (5).
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Figure B.5. HPLC chromatogram of linear CNGRC.

Figure B.6. Mass spectrum of linear CNGRC
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Figure B.7. HPLC chromatogram of cyclic CNGRC

Figure B.8. Mass spectrum of cyclic CNGRC
91

Figure

B.9

HPLC

chromatogram

of

conjugate

Figure B.10. Mass spectrum of conjugate 2 (Mal-Glut-CNGRC).

92

2

(Mal-Glut-CNGRC)

Figure B.11 HPLC chromatogram of linear mPeg-CNGRC-mal

Figure B.12. Mass Spectra of linear CNGRC mPeg-CNGRC-mal
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Figure B.13. HPLC chromatogram of conjugate 6 (cyclic mPeg-CNGRC-mal)

Figure B.14. Mass spectrum of conjugate 6 (cyclic mPeg-CNGRC-mal).
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Figure B.15. Mass spectrum of conjugate 7 (cyclic mPeg-CNGRC-Pt).
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Figure B.16. Mass spectrum of conjugate 8 (cyclic mPeg-CNGRC-Pten).

Figure B.17. HPLC chromatogram of free peptide 9 (cyclic mPeg-CNGRC)
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Figure B.18. Mass spectrum of cyclic mPeg-CNGRC (9).
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